UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March 31,~~September 30, 2021

☐

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to to

Commission file number: 001-38659

BIOSIG TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)


Delaware		26-4333375
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

~~54 Wilton~~55 Greens Farms Road, ~~2nd~~1st Floor Westport, CT	~~06880~~	~~(203) 409-5444~~06880
(Address of principal executive office)		(Zip Code)

(203) 409-5444
(Registrant’s telephone number, ~~Including~~including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	BSGM	The NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~May 14,~~November 15, 2021, there were ~~32,180,479~~35,310,627 shares of registrant’s common stock outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

	ITEM 1.	Financial Statements

		Condensed consolidated balance sheets as of ~~March 31,~~September 30, 2021 (unaudited) and December 31, 2020	3

		Condensed consolidated statements of operations for the three and nine months ended ~~March 31,~~September 30, 2021 and 2020 (unaudited)	4

		Condensed consolidated statement of changes in equity for the three and nine months ended ~~March 31,~~September 30, 2021 (unaudited)	5

		Condensed consolidated statement of changes in equity for the three and nine months ended ~~March 31,~~September 30, 2020 (unaudited)	6

		Condensed consolidated statements of cash flows for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and 2020 (unaudited)	7

		Notes to condensed consolidated financial statements (unaudited)	~~8-27~~8-33

	ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	~~28-34~~34-44
	ITEM 3.	Quantitative and Qualitative Disclosures about Market Risk	3545
	ITEM 4.	Controls and Procedures	3545

PART II. OTHER INFORMATION

	ITEM 1.	Legal Proceedings	3646
	ITEM 1A.	Risk Factors	3646
	ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3647
	ITEM 3.	Defaults Upon Senior Securities	3647
	ITEM 4.	Mine Safety Disclosures	3647
	ITEM 5.	Other Information	3647
	ITEM 6.	Exhibits	3748

	SIGNATURES		3849

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BIOSIG TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Par Value and Share Amounts)

	March 31,			December 31,			September 30,			December 31,
	2021			2020			2021			2020
	(unaudited)						(unaudited)
ASSETS
Current assets:
Cash	$	22,475		$	28,268		$	17,535		$	28,268
Accounts receivable, net								100			-
Employee advances								50			-
Inventory		650			768			1,881			768
Prepaid expenses and vendor deposits		209			301			433			301
Total current assets		23,334			29,337			19,999			29,337

Property and equipment, net		381			289			557			289

Right-to-use assets, net		356			306			693			306

Other assets:
Patents, net		341			346			331			346
Trademarks		1			1			1			1
Prepaid expenses, long term		1			5			-			5
Deposits		102			102			92			102

Total assets	$	24,516		$	30,386		$	21,673		$	30,386

LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses, including $147 and $317 to related parties as of March 31, 2021 and December 31, 2020, respectively	$	3,459		$	4,722
Accounts payable and accrued expenses, including $80 and $317 to related parties as of September 30, 2021 and December 31, 2020, respectively							$	2,169		$	4,722
Deferred revenue, short term		32			0			32			-
Dividends payable		75			73			79			73
Lease liability, short term		330			313			291			313
Total current liabilities		3,896			5,108			2,571			5,108

Deferred revenue, long term		29			0			13			-
Lease liability, long term		28			1			409			1
Total long-term debt		57			1			422			1

Total liabilities		3,953			5,109			2,993			5,109

Commitments and contingencies (Note 11)

Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of March 31, 2021 and December 31, 2020		105			105
Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; liquidation preference of $105 as of September 30, 2021 and December 31, 2020								105			105

Equity:
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock, none issued of Series F Preferred Stock		0			0			-			-
Common stock, $0.001 par value, authorized 200,000,000 shares, 32,114,781 and 30,764,792 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively		32			31
Common stock, $0.001 par value, authorized 200,000,000 shares, 35,254,860 and 30,764,792 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively								35			31
Additional paid in capital		185,168			181,344			198,380			181,344
Accumulated deficit		(165,324	)		(157,005	)		(180,278	)		(157,005	)
Total stockholders' equity attributable to BioSig Technologies, Inc.		19,876			24,370			18,137			24,370
Non-controlling interest		582			802			438			802
Total equity		20,458			25,172			18,575			25,172

Total liabilities and equity	$	24,516		$	30,386		$	21,673		$	30,386

See the accompanying notes to the unaudited condensed consolidated financial statements

Table of Contents

BIOSIG TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Par Value and Share Amounts)
(unaudited)

	Three months ended March 31,						Three months ended September 30,						Nine months ended September 30,
	2021			2020			2021			2020			2021			2020
Revenue:
Product sales	$	115		$	0		$	100		$	-		$	414		$	-
Service		3			0			8			-			19			-
Total Revenue		118			0
Total revenue								108			-			433			-

Cost of goods sold		99			0			38			-			199			-

Gross profit		19			0			70			-			234			-

Operating expenses:
Research and development		1,266			4,927			1,315			4,911			4,248			15,556
General and administrative		7,271			7,855			6,505			8,165			20,256			32,629
Depreciation and amortization		42			21			51			24			142			67
Total operating expenses		8,579			12,803			7,871			13,100			24,646			48,252

Loss from operations		(8,560	)		(12,803	)		(7,801	)		(13,100	)		(24,412	)		(48,252	)

Other income (expense):
Interest income, net		1			40			1			2			2			45
Gain on settlement of debt								553			-			553			-
Loss on foreign currency translation								-			-			-			(1	)

Loss before income taxes		(8,559	)		(12,763	)		(7,247	)		(13,098	)		(23,857	)		(48,208	)

Income taxes (benefit)		0			0			-			-			-			-

Net loss		(8,559	)		(12,763	)		(7,247	)		(13,098	)		(23,857	)		(48,208	)

Non-controlling interest		240			1,428			(6	)		1,696			584			6,282

Net loss attributable to BioSig Technologies, Inc.		(8,319	)		(11,335	)		(7,253	)		(11,402	)		(23,273	)		(41,926	)

Preferred stock dividend		(2	)		(5	)		(2	)		(2	)		(7	)		(11	)

NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$	(8,321	)	$	(11,340	)	$	(7,255	)	$	(11,404	)	$	(23,280	)	$	(41,937	)

Net loss per common share, basic and diluted	$	(0.26	)	$	(0.46	)	$	(0.21	)	$	(0.38	)	$	(0.71	)	$	(1.56	)

Weighted average number of common shares outstanding, basic and diluted		31,584,142			24,389,249			34,856,502			29,750,378			32,881,932			26,900,383

See the accompanying notes to the unaudited condensed consolidated financial statements

Table of Contents

	Common stock				Additional Paid in			Accumulated			Non-controlling						Common stock				Additional Paid in			Accumulated			Non-controlling
	Shares		Amount		Capital			Deficit			Interest			Total			Shares		Amount		Capital			Deficit			Interest			Total
Balance, December 31, 2020		30,764,792	$	31	$	181,344		$	(157,005	)	$	802		$	25,172			30,764,792	$	31	$	181,344		$	(157,005	)	$	802		$	25,172
Common stock issued for services		406,692		-		1,777			-			-			1,777			406,692		-		1,777			-			-			1,777
Common stock issued upon exercise of options at $2.96 per share		9,375		-		28			-			-			28			9,375		-		28			-			-			28
Sale of common stock under At-the-market offering, net of transaction expenses of $40		251,720		-		1,300			-			-			1,300			251,720		-		1,300			-			-			1,300
Stock based compensation		682,202		1		721			-			20			742			682,202		1		721			-			20			742
Preferred stock dividend		-		-		(2	)		-			-			(2	)		-		-		(2	)		-			-			(2	)
Net loss		-		-		-			(8,319	)		(240	)		(8,559	)		-		-		-			(8,319	)		(240	)		(8,559	)
Balance, March 31, 2021 (unaudited)		32,114,781	$	32	$	185,168		$	(165,324	)	$	582		$	20,458			32,114,781		32		185,168			(165,324	)		582			20,458
Common stock for services																		36,948		-		140			-			-			140
Change in fair value of modified options																		-		-		313			-			8			321
Stock based compensation																		53,750		-		1,518			-			134			1,652
Preferred stock dividend																		-		-		(3	)		-			-			(3	)
Net loss																		-		-		-			(7,701	)		(350	)		(8,051	)
Balance, June 30, 2021 (unaudited)																		32,205,479		32		187,136			(173,025	)		374			14,517
Sale of common stock, net transactional costs of $995																		2,500,000		3		9,002			-			-			9,005
Common stock issued for services																		409,631		-		1,354			-			-			1,354
Stock based compensation																		139,750		-		890			-			58			948
Preferred stock dividend																						(2	)		-			-			(2	)
Net loss																		-		-		-			(7,253	)		6			(7,247	)
Balance, September 30, 2021 (unaudited)																		35,254,860	$	35	$	198,380		$	(180,278	)	$	438		$	18,575

See the accompanying notes to the unaudited condensed consolidated financial statements

Table of Contents

	Common stock				Additional Paid in			Accumulated			Non-controlling						Common stock				Additional Paid in			Accumulated			Non-controlling
	Shares		Amount		Capital			Deficit			Interest			Total			Shares		Amount		Capital			Deficit			Interest			Total
Balance, December 31, 2019		23,323,087	$	23	$	115,910		$	(104,787	)	$	515		$	11,661			23,323,087	$	23	$	115,910		$	(104,786	)	$	515		$	11,662
Sale of common stock		2,500,000		2		9,050			-			-			9,052			2,500,000		2		9,050			-			-			9,052
Common stock issued upon conversion of Series C Preferred Stock at $3.75 per share		2,667		-		10			-			-			10			2,667		-		10			-			-			10
Common stock issued settlement of Series C Preferred Stock accrued dividends at $5.39 per share		1,083		-		6			-			-			6			1,083		-		6			-			-			6
Common stock issued upon cashless exercise of warrants		10,574		-		-			-			-			-			10,574		-		-			-			-			-
Common stock issued upon cashless exercise of options		11,141		-		-			-			-			-			11,141		-		-			-			-			-
Common stock issued upon exercise of warrants at an average of $3.75 per share		80,432		1		301			-			-			302			80,432		1		301			-			-			302
Fair value of subsidiary shares issued to acquire research and development from Trek Therapeutics, PBC		-		-		2,440			-			735			3,175			-		-		2,440			-			735			3,175
Stock based compensation		81,334		-		3,628			-			785			4,413			81,334		-		3,628			-			785			4,413
Preferred stock dividend		-		-		(5	)		-			-			(5	)		-		-		(5	)		-			-			(5	)
Net loss		-		-		-			(11,335	)		(1,428	)		(12,763	)		-		-		-			(11,336	)		(1,428	)		(12,764	)
Balance, March 31, 2020 (unaudited)		26,010,318	$	26	$	131,340		$	(116,122	)	$	607		$	15,851			26,010,318		26		131,340			(116,122	)		607			15,851
Sale of common stock																		2,187,500		2		16,160			-			-			16,162
Sale of subsidiary shares to non-controlling interest																		-		-		7,124			-			3,468			10,592
Common stock issued for services																		15,038		-		108			-			-			108
Fair value of subsidiary shares issued to acquire research and development																		-		-		1,051			-			249			1,300
Common stock issued upon conversion of Series C Preferred Stock at $3.75 per share																		26,667		-		100			-			-			100
Common stock issued for settlement of Series C Preferred Stock accrued dividends at $4.47 per share																		14,433		-		65			-			-			65
Common stock issued upon cashless exercise of warrants																		2,266		-		-			-			-			-
Common stock issued upon cashless exercise of options																		149,602		-		-			-			-			-
Common stock issued upon exercise of options at an average of $4.66 per share																		478,451		1		2,228			-			-			2,229
Common stock issued upon exercise of warrants at an average of $3.87 per share																		189,388		-		733			-			-			733
Stock based compensation																		53,000		-		9,595			-			1,628			11,223
Preferred stock dividend																		-		-		(5	)		-			-			(5	)
Net loss																		-		-		-			(19,188	)		(3,158	)		(22,346	)
Balance, June 30, 2020 (unaudited)																		29,126,663		29		168,499			(135,310	)		2,794			36,012
Sale of common stock in September 2020 under At-the market offering, net of transaction expenses of $182																		150,000		-		1,002			-			-			1,002
Common stock for services																		488,000		1		3,442			-			-			3,443
Common stock issued upon exercise of options at an average of $4.54 per share																		108,374		-		492			-			-			492
Common stock issued upon exercise of warrants at an average of $3.95 per share																		160,159		-		632			-			-			632
Stock based compensation																		85,000		-		1,163			-			222			1,385
Preferred stock dividend																		-		-		(2	)		-			-			(2	)
Net loss																		-		-		-			(11,402	)		(1,696	)		(13,098	)
Balance, September 30, 2020 (unaudited)																		30,118,196	$	30	$	175,228		$	(146,712	)	$	1,320		$	29,866

See the accompanying notes to the unaudited condensed consolidated financial statements

Table of Contents

BIOSIG TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands, Except Par Value and Share Amounts)
(unaudited)

	Three months ended March 31,						Nine months ended September 30,
	2021			2020			2021			2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(8,559	)	$	(12,763	)	$	(23,857	)	$	(48,208	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization		42			21			142			67
Amortization of right to use assets		111			113			334			342
Equity based compensation		2,519			4,413			6,613			20,573
Gain on settlement of debt								(553	)		-
Change in fair value of modified options								321			-
Fair value of subsidiary stock issued to acquire research and development from Trek Therapeutics, PBC		0			3,174			-			3,175
Fair value of subsidiary stock issued to acquire research and development											1,300
Changes in operating assets and liabilities:
Accounts receivable								(100	)		-
Employee advances								(50	)		-
Inventory		118			(222	)		(1,113	)		(229	)
Vendor deposits		18			(100	)
Prepaid expenses		78			(10	)
Prepaid expenses and other								(117	)		(180	)
Deferred revenue		61			0			45			-
Accounts payable and accrued expenses		(1,263	)		(456	)		(1,999	)		3,005
Operating lease liabilities		(116	)		(112	)		(334	)		(342	)
Net cash used in operating activities		(6,991	)		(5,942	)		(20,668	)		(20,497	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(130	)		(20	)		(398	)		(60	)
Net cash used in investing activity		(130	)		(20	)		(398	)		(60	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock, net of issuance costs		0			9,052			9,005			25,214
Proceeds from sale subsidiary stock to non-controlling interest, net of issuance costs								-			10,592
Proceeds from sale of common stock under a At-the-market offering, net of issuance costs		1,300			0			1,300			1,002
Proceeds from exercise of options		28			0			28			2,722
Proceeds from exercise of warrants		0			302			-			1,667
Net cash provided by financing activities		1,328			9,354			10,333			41,197

Net (decrease) increase in cash and cash equivalents		(5,793	)		3,392			(10,733	)		20,640

Cash and cash equivalents, beginning of the period		28,268			12,108			28,268			12,108
Cash and cash equivalents, end of the period	$	22,475		$	15,500		$	17,535		$	32,748

Supplemental disclosures of cash flow information:
Cash paid during the period for interest	$	0		$	0		$	-		$	-
Cash paid during the period for income taxes	$	0		$	0		$	-		$	-

Noncash investing and financing activities:
Common stock issued upon conversion of Series C Preferred Stock and accrued dividends	$	0		$	16		$	-		$	180
Dividend payable on preferred stock charged to additional paid in capital	$	2		$	5		$	7		$	12
Record right-to-use assets and related lease liability	$	218		$	0		$	800		$	-

See the accompanying notes to the unaudited condensed consolidated financial statements

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

BioSig Technologies, Inc. was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the standard of care in electrophysiology with its initial product offering, the PURE EP™ System, designed for enhanced cardiac signal acquisition, digital signal processing, and analysis during ablation of cardiac arrhythmias. The Company has generated minimal revenue to date and consequently its operations are subject to all risks inherent in business enterprises in early commercialization stage.

On November 7, 2018, the Company formed a subsidiary under the laws of the State of Delaware originally under the name of NeuroClear Technologies, Inc. which was renamed to ViralClear Pharmaceuticals, Inc. (“ViralClear”) in March 2020. The subsidiary was established to pursue additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that showed potential for the treatment of COVID-19. ~~As of March 31, 2021,~~Since late 2020, ViralClear ~~had~~has been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology.

In 2019 and 2020, ViralClear sold an aggregate of 1,965,240 shares of its common stock to investors for net proceeds of $15.6 million and issued an aggregate of 894,869 shares of its common stock in connection with acquiring assets and with know-how agreements. As of ~~March 31,~~September 30, 2021, the Company had a majority interest in ViralClear of ~~70.2%~~68.44%.

On July 2, 2020, the Company formed an additional subsidiary, NeuroClear Technologies, Inc., a Delaware corporation.

The unaudited condensed consolidated financial statements include the accounts of BioSig Technologies, Inc., its wholly owned subsidiary, NeuroClear Technologies, Inc. and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. as the “Company” or “BioSig”.

The unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

The condensed consolidated balance sheet as of December 31, 2020 has been derived from audited financial statements.

Operating results for the three and nine months ended ~~March 31,~~September 30, 2021 are not necessarily indicative of results that may be expected for the year ending December 31, 2021. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2020 filed with the Company’s Form 10-K with the Securities and Exchange Commission on March 15, 2021.

COVID-19

On March 11, 2020, the World Health Organization declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health emergency. The full public-health impact of the ongoing pandemic is currently indeterminable and rapidly evolving, and the related health crisis has adversely affected and may continue to adversely affect the global economy, resulting in delaying to our commercialization objectives of the PURE EP Systems into ~~2021.~~2022.

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

NOTE 2 – MANAGEMENT’S LIQUIDITY PLANS

BioSig Technologies, Inc.’s primary efforts are principally devoted to improving the standard care of electrophysiology with its PURE EP System’s enhanced signal acquisition, digital signal processing, and analysis during ablation of cardiac arrhythmias; NeuroClear’s and ViralClear’s efforts are in developing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. Further, the Company has generated minimal revenues and there is no assurance that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's ongoing research and development will be successfully completed or that any product will be commercially viable.

We expect to incur losses from operations for the near future. Additionally, we expect to incur increasing marketing and commercialization expenses related to our PURE EP system in addition to research and development costs relating to PURE EP and other product candidates, including expenses related to clinical trials. We expect that our general and administrative expenses will increase in the future as we expand our business development, add infrastructure and incur additional costs related to being a public company, including incremental audit fees, investor relations programs and increased professional services.

If additional financing is not available or is not available on acceptable terms, we may be required to delay, reduce the scope of or eliminate our research and development programs, reduce our commercialization efforts or obtain funds through arrangements with collaborative partners or others that may require us to relinquish rights to certain product candidates that we might otherwise seek to develop or commercialize independently.

At ~~March 31,~~September 30, 2021, the Company had working capital of approximately ~~$19.4~~$17.4 million. During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, the Company raised approximately $9.0 million, net of expenses, through the sale of common stock and $1.3 million, net of expenses, through an At-the-market offering. The Company has begun its commercial operations generating revenues with the sale of the PURE EP device. At ~~March 31,~~September 30, 2021 the Company has effective Forms S-3, shelf registration statements for an aggregate of ~~$116.0~~$107.0 million.

At ~~March 31,~~September 30, 2021, the Company had cash of approximately ~~$22.5~~$17.5 million ~~which~~through the date of the filing of this report and with the expected commercial growth, constitutes sufficient funds for the Company to meet its commercialization efforts, research and development and other funding requirements for at least the next 12 months from the date of issuance of these unaudited financial statements.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of these unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of long-term operating leases, patent capitalization, fair value of acquired assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.

Revenue Recognition

The Company derives its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software upgrades in connection with the system.

The Company recognizes revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that an entity recognizes revenue to depict

the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

The Company determines revenue recognition through the following five steps:

●

Identify the contract with the customer;

●

Identify the performance obligations in the contract;

●

Determine the transaction price;

●

Allocate the transaction price to the performance obligation in the contract; and

●

Recognize revenue when, or as, the performance obligations are satisfied.

~~Table of Contents~~

~~BIOSIG TECHNOLOGIES, INC.~~

~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~MARCH 31, 2021~~

~~(unaudited)~~

Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If the Company determines that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Support, maintenance, and software upgrades are performance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial sale of the PURE EP System and do not have the right to terminate their contracts unless we fail to perform material obligations.

The Company may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements.

The Company records accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue.

The Company’s unconditional right to consideration for goods and services transferred to the customer is included in accounts receivable, net (if any) in the Company’s unaudited condensed consolidated balance sheet.

A reconciliation of contract liabilities with customers is presented below:

	Balance at December 31, 2020		Consideration Received		Recognized in Revenue			Balance at March 31, 2021		Balance at December 31, 2020 (000’s)		Consideration Received (000’s)		Recognized in Revenue (000’s)			Balance at September 30, 2021 (000’s)
Product revenue	$	0	$	115,367	$	(115,367	)	$	0	$	-	$	414	$	(414	)	$	-
Service revenue		0		64,312		(2,680	)		61,632		-		64		(19	)		45
Total	$	0	$	179,679	$	(118,047	)	$	61,632	$	-	$	478	$	(433	)	$	45

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

The table below summarizes our deferred revenue as of ~~March 31,~~September 30, 2021 and December 31, 2020:

	March 31, 2021		December 31, 2020		September 30, 2021 (000’s)		December 31, 2020 (000’s)
Deferred revenue-current	$	32,156	$	0	$	32	$	-
Deferred revenue-noncurrent		29,476		0		13		-
Total deferred revenue	$	61,632	$	0	$	45	$	-

We had one customer which accounted for approximately ~~100%~~93% of our revenue in the three months ended ~~March 31,~~September 30, 2021 and two customers which accounted for approximately 69% and 31% of our revenue in the nine months ended September 30, 2021.

At September 30, 2021, the Company had one customer representing 100% of the outstanding accounts receivable.

Cost of Goods Sold

Cost of goods sold consists primarily of the delivered cost of our medical device(s) sold.

Allowance for Doubtful Accounts

The Company adjusts accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for doubtful accounts for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of the client and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. The allowance for doubtful accounts was $0 at September 30, 2021. The Company believes that its reserve is adequate, however results may differ in future periods. For the nine months ended September 30, 2021 and 2020, bad debt expense totaled $0.

Fair Value of Financial Instruments

Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed.

~~Table of Contents~~

~~BIOSIG TECHNOLOGIES, INC.~~

~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~MARCH 31, 2021~~

~~(unaudited)~~

The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and ASC 825-10, which permits entities to choose to measure many financial instruments and certain other items at fair value.

Concentrations of Credit Risk

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At ~~March 31,~~September 30, 2021 and December 31, 2020, deposits in excess of FDIC limits were ~~$22.0~~$17.0 million and $27.8 million, respectively.

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

Inventory

The inventory is comprised of work in process and finished goods available for sale and are stated at the lower of cost or net realizable value using ~~the~~specific identification method for serial numbered inventory and first-in, first-out method offor all other inventory for valuation. The inventory at ~~March 31,~~September 30, 2021 and December 31, 2020 were ~~$649,937~~$1,881,007 and $768,319, ~~respectively.~~respectively, comprised of finished goods.

Prepaid Expenses and Vendor Deposits

Prepaid expenses and vendor deposits are comprised of prepaid insurance, operating expenses and other prepayments.

Leases

The Company determines if a contractual arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and noncurrent operating lease liabilities on the Company’s unaudited condensed consolidated balance sheet. The Company evaluates and classifies leases as operating or finance leases for financial reporting purposes. The classification evaluation begins at the commencement date and the lease term used in the evaluation includes the non-cancellable period for which the Company has the right to use the underlying asset, together with renewal option periods when the exercise of the renewal option is reasonably certain and failure to exercise such option which result in an economic penalty. All the Company’s real estate leases are classified as operating leases. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term.

The lease payments included in the present value are fixed lease payments. As most of the Company’s leases do not provide an implicit rate, the Company estimates its collateralized incremental borrowing rate, based on information available at the commencement date, in determining the present value of lease payments. The Company applies the portfolio approach in applying discount rates to its classes of leases. The operating lease ROU assets include any payments made before the commencement date. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company does not currently have subleases. The Company does not currently have residual value guarantees or restrictive covenants in its leases.

Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.

Impairment of Long-lived Assets

The Company recognizes an impairment of long-lived assets used in operations, other than goodwill, when events or circumstances indicate that the asset might be impaired and the estimated undiscounted cash flows to be generated by those assets over their remaining lives are less than the carrying amount of those items. The net carrying value of assets not recoverable is reduced to fair value, which is typically calculated using the discounted cash flow method. The Company did not recognize and record any impairments of long-lived assets used in operations during the three and nine months ended ~~March 31,~~September 30, 2021 and 2020.

1112

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

Research and Development Costs

The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and ~~developments~~development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1.3 million and ~~$4.9~~$4.2 million for the three and nine months ended ~~March 31,~~September 30, 2021, and $4.9 million and $15.6 million for the three and nine months ended September 30, 2020, respectively.

Net Income (loss) Per Common Share

The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

The computation of basic and diluted loss per share as of ~~March 31,~~September 30, 2021 and 2020 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

	March 31, 2021		March 31, 2020		September 30, 2021		September 30, 2020
Series C convertible preferred stock		47,659		81,465		64,292		44,194
Options to purchase common stock		3,780,037		3,828,896		4,037,122		3,509,956
Warrants to purchase common stock		1,436,200		1,963,030		818,910		1,604,668
Restricted stock units to acquire common stock		346,000		181,334		182,500		168,334
Totals		5,609,896		6,054,725		5,102,824		5,327,152

Stock Based Compensation

The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award as measured on the grant date. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.

Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods.

~~Warranty~~

The Company generally warrants its products to be free from material defects and to conform to material specifications for a period of up to two (2) years. Warranty expense is estimated based primarily on historical experience and is reflected in the financial statements.

1213

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

Patents, Net

The Company capitalizes certain initial asset costs in connection with patent applications including registration, documentation and other professional fees associated with the application. Patent costs incurred prior to the Company’s U.S. Food and Drug Administration (“FDA”) 510(k) application on March 28, 2018 were charged to research and development expense as incurred. Commencing upon first in-man trials on February 18 and 19, 2019, capitalized costs are amortized to expense using the straight-line method over the lesser of the legal patent term or the estimated life of the product of 20 years. During the three and nine months ended ~~March 31,~~September 30, 2021, ~~and 2020,~~ the Company recorded amortization of $4,751 and ~~$4,751~~$14,254; and $4,752 and $14,254 for the three and nine months ended September 30, 2020 to current period operations, respectively.

Warranty

Non-controlling Interest

The Company’s non-controlling interest represents the non-controlling shareholders ownership interests related to the Company’s subsidiary, ~~ViralClear Pharmaceuticals, Inc.~~ViralClear. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the unaudited condensed consolidated balance sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company’s common shareholders on the face of the unaudited condensed consolidated statements of operations. The Company’s equity interest in ViralClear is ~~70.2%~~68.44% and the non-controlling stockholders’ interest is ~~29.8%~~31.56% as of ~~March 31,~~September 30, 2021. This is reflected in the unaudited condensed consolidated statements of changes in equity.

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The information disclosed herein represents all of the material financial information related to the Company’s principal operating segments. (See Note 12 – Segment Reporting).

Reclassifications

Certain reclassifications have been made to prior periods’ data to conform with the current year’s presentation. These reclassifications had no effect on reported income or losses.

Recent Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

~~NOTE~~4 – ~~PROPERTY AND EQUIPMENT~~

~~Property and equipment as of March 31, 2021 and December 31, 2020 is summarized as follows:~~

March 31,
2021

December 31,
2020

Computer equipment
$ 315,532 $ 232,902
Furniture and fixtures
79,147 75,127
Manufacturing equipment
34,377 34,377
Testing/Demo equipment
139,225 96,000
Total
568,281 438,406
Less accumulated depreciation
(186,880
)
(149,846
)
Property and equipment, net
$ 381,401 $ 288,560

1314

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

NOTE4 – PROPERTY AND EQUIPMENT

Property and equipment as of September 30, 2021 and December 31, 2020 is summarized as follows:

	September 30, 2021 (000’s)			December 31, 2020 (000’s)
Computer equipment	$	377		$	234
Furniture and fixtures		83			75
Manufacturing equipment		153			34
Testing/Demo equipment		145			96
Leasehold improvements		77			-
Total		835			439
Less accumulated depreciation		(278	)		(150	)
Property and equipment, net	$	557		$	289

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. Leasehold improvements are depreciated over the related expected lease term. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.

Depreciation expense was ~~$36,834~~$46,205 and ~~$16,264~~$128,152 for three and nine months ended ~~March 31,~~September 30, 2021 and $19,117 and $52,838 for the three and nine months ended September 30, 2020, respectively.

NOTE 5 – RIGHT TO USE ASSETS AND LEASE LIABILITY

Operating leases:

On February 10, 2021 the Company entered into a Sixth Amendment to the Office Lease at 12424 Wilshire Blvd in Los Angeles dated August 9, 2011 – it is the Fourth Extended Term with respect to Suite 745 and the Expansion Term with respect to Suite 740 which is from July 1, 2021 until June 30, 2022 with a fixed monthly rent equal to $13,702 (down from $16,289); and the security deposit will be reduced by $5,448 so that the balance remaining shall be $27,404.

The Company determined that the Sixth Amendment was a lease modification and accordingly reassessed the lease classification, remeasured the lease liability and adjusted the right-to-use asset. At February 10, 2021 the Company removed the remaining right-to-use net assets of $60,881 and related lease liability of $63,076 and recorded right-to-use assets and related lease liability of $217,903.

On ~~October 1, 2019,~~August 2, 2021, the Company ~~entered into a~~exercised its option to extend its Rochester, Minnesota lease ~~agreement whereby the Company leased~~of approximately 1,400 square feet of office space ~~in Rochester, Minnesota commencing November 1, 2019 and~~for two additional years expiring on October 31, ~~2021 at an initial~~2023 with a fixed monthly rate of ~~$3,411 per month with escalating payments.~~ $3,513, increasing to $3,618 for the second year.

The ~~lease agreement includes an option to extend~~Company determined that the lease ~~for two additional periods~~option exercised was a lease modification and accordingly reassessed the lease classification, remeasured the lease liability and adjusted the right-to-use asset. On August 2, 2021 the Company removed the remaining right-to-use net assets of ~~two years each past its initial term.~~$10,247 and related lease liability of $10,400 and recorded right-to-use assets and related lease liability of $89,629. At the lease modification date, the Company estimated the lease liability and the right of use assets at present value using the Company’s estimated incremental borrowing rate of 8%6.5%.

~~As of March 31,~~On August 3, 2021, the Company ~~had outstanding 5 leases with aggregate payments~~entered into a sublease agreement whereby the Company leased approximately 6,590 square feet of ~~$38,535 per month,~~office space at 55 Greens Farms Road, Westport, Connecticut commencing September 1, 2021 and expiring ~~through~~ December 31, ~~2022.~~

~~Right~~2024 (40 months) at the initial rate beginning January 1, 2022 of $14,828 with escalating payments. In connection with the lease, the Company paid a security deposit of $14,232. There is no option to ~~use~~extend the lease past its initial term. At the lease commencement date, the Company estimated the lease liability and right-to-use assets ~~is summarized below:~~

March 31,
2021

December 31,
2020

Right to use assets, net
$ 808,511 $ 1,087,075
Less accumulated depreciation
(452,245
)
(780,591
)
Right to use assets, net
$ 356,266 $ 306,484

~~During~~at present value using the ~~three months ended March 31,~~Company’s incremental borrowing rate of 6.5% and determined their initial present values, at inception, of $492,876. In conjunction with the lease, the Company terminated, without penalty, the sublease at 54 Wilton Road, Westport, CT effective September 4, 2021 and ~~2020,~~removed the ~~Company recorded $118,601~~remaining right-to-use assets of $36,756 and ~~$119,408 as~~related lease liability of $37,625 with a credit to rent expense of $868 relating to ~~current period operations, respectively.~~the lease termination.

~~Lease liability is summarized below:~~

March 31,
2021

December 31,
2020

Total lease liability
$ 358,034 $ 313,411
Less: short term portion
(329,924
)
(312,691
)
Long term portion
$ 28,110 $ 720

1415

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

As of September 30, 2021, the Company had outstanding 5 leases with aggregate payments of $17,315 per month, expiring through December 31, 2024.

Right to use assets is summarized below:

	September 30, 2021 (000’s)			December 31, 2020 (000’s)
Right to use assets, net	$	803		$	1,087
Less accumulated amortization		(110	)		(781	)
Right to use assets, net	$	693		$	306

During the three and nine months ended September 30, 2021, the Company recorded $120,127 and $365,366 and $124,437 and $370,656 for the three and nine months ended September 30, 2020 as lease expense to current period operations, respectively.

Lease liability is summarized below:

	September 30, 2021 (000’s)			December 31, 2020 (000’s)
Total lease liability	$	700		$	314
Less: short term portion		(291	)		(313	)
Long term portion	$	409		$	1

Maturity analysis under these lease agreements are as ~~follows:~~follows (000’s):

Remainder of 2021	$	289,195		$	52
Year ended December 31, 2022		83,412			304
Year ended December 31, 2023					220
Year ended December 31, 2024					191
Total		372,607			767
Less: Present value discount		(14,573	)		(67	)
Lease liability	$	358,034		$	700

Lease expense for the three months ended ~~March 31,~~September 30, 2021 and 2020 was comprised of the following:

	March 31, 2021		March 31, 2020		September 30, 2021 (000’s)		September 30, 2020 (000’s)
Operating lease expense	$	110,932	$	113,262	$	105	$	115
Short-term lease expense		7,429		5,655		15		9
Variable lease expense		240		491
Total	$	118,601	$	119,408	$	120	$	124

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

Lease expense for the nine months ended September 30, 2021 and 2020 was comprised of the following:

	September 30, 2021 (000’s)		September 30, 2020 (000’s)
Operating lease expense	$	334	$	342
Short-term lease expense		31		28
Variable lease expense		-		1
Total	$	365	$	371

NOTE 6 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses at ~~March 31,~~September 30, 2021 and December 31, 2020 consist of the following:

	March 31, 2021		December 31, 2020		September 30, 2021 (000’s)		December 31, 2020 (000’s)
Accrued accounting and legal	$	188,556	$	176,735	$	163	$	177
Accrued reimbursements and travel		25,072		55,836		47		56
Accrued consulting		157,102		255,693		84		256
Accrued research and development expenses		2,411,067		3,127,404		221		3,127
Accrued product purchases		4,663		30,350		68		30
Accrued marketing		119,061		0		49		-
Accrued office and other		91,926		127,315		25		127
Accrued payroll		448,255		935,471		499		936
Accrued settlement related to arbitration		13,333		13,333		1,013		13
	$	3,459,035	$	4,722,137	$	2,169	$	4,722

NOTE 7 – SERIES C 9% CONVERTIBLE PREFERRED STOCK

Series C 9% Convertible Preferred Stock

On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”).

The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder.

As a result of an amendment to the conversion price of our Series C Preferred Stock, the conversion price effective as of December 31, 2020 was $3.75 per share, subject to certain reset provisions. On August 17, 2021, the conversion price was reset to $2.98 per share. The effect was de minimis.

1517

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

As a result of an amendment to the conversion price of our Series C Preferred Stock, the conversion price effective as of March 31, 2021 and December 31, 2020 was $3.75 per share, subject to certain reset provisions.

The Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated value of $1,000 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. As of ~~March 31,~~September 30, 2021, the aggregate stated value of our Series C Preferred Stock was $105,000. The triggering events include our being subject to a judgment of greater than $100,000 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock occur, the holders of our Series C Preferred Stock may demand redemption, an obligation the Company may not have the ability to meet at the time of such demand. The Company will be required to pay interest on any amounts remaining unpaid after the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law. Accordingly, the Company has classified the Series C Preferred Stock as a mezzanine obligation in the accompanying consolidated balance sheets.

Series C Preferred Stock issued and outstanding totaled 105 as of ~~March 31,~~September 30, 2021 and December 31, 2020. As of ~~March 31,~~September 30, 2021 and December 31, 2020, the Company has accrued ~~$74,547~~$79,285 and ~~$72,217~~$72,517 dividends payable on the Series C Preferred Stock.

NOTE 8 – STOCKHOLDER EQUITY

Shareholder rights plan

On July 14, 2020, our board of directors adopted a stockholder rights plan (the “Rights Plan”) and declared a dividend of one preferred share purchase right for each outstanding share of BioSig’s common stock to stockholders of record on July 27, 2020, and one right will be issued for each new share of common stock issued thereafter. Each right will initially trade with common stock, and will allow its holder to purchase from BioSig one one-thousandth of a share of Series F Junior Participating Preferred stock, par value $0.001 per share, for an exercise price of $50.00, once the rights become exercisable. In the event that a person or group acquires beneficial ownership of 12% or more of BioSig’s then outstanding common stock, subject to certain exceptions, each right would entitle its holder (other than such person or members of such group) to purchase additional shares of BioSig’s common stock having a market value of two times the exercise price of the right. In addition, at any time after a person or group acquires 12% or more of BioSig’s outstanding common stock (unless such person or group acquires 50% or more), the Board may exchange one share of BioSig’s common stock for each outstanding right (other than rights owned by such person or group, which would have become void). The Rights Plan could make it more difficult for a third party to acquire control of BioSig or a large block of our common stock without the approval of our board of directors. The rights ~~will expire~~expired on July 13, 2021, unless terminated earlier by our board of directors.

Preferred stock

The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of ~~March 31,~~September 30, 2021, and December 31, 2020, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock and 200,000 shares of Series F Preferred Stock. As of ~~March 31,~~September 30, 2021, and December 31, 2020, there were no outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock.

Common stock

BioSig Technologies, Inc.

The Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. As of ~~March 31,~~September 30, 2021 and December 31, 2020, the Company had ~~32,114,781~~35,254,860 and 30,764,792 shares issued and outstanding, respectively.

In January 2021, the Company issued an aggregate of 658,868 shares of its common stock for services at a fair value previously recorded in 2020 of $2,658,224.

1618

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, the Company issued ~~406,692~~853,271 shares of common stock for services at a fair value of ~~$1,777,619.~~$3,271,340.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, the Company issued 9,375 shares of common stock in exchange for proceeds of $27,750 from the exercise of options.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, the Company issued an aggregate of ~~23,334~~216,834 shares of its common stock for vested restricted stock ~~units as stock-based compensation.~~units.

Sale of common stock

On July 2, 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Laidlaw & Company (UK) Ltd. (the “Underwriter”), relating to an underwritten public offering of 2,500,000 shares of the Company’s common stock, $0.001 par value per share. All of the shares were sold by the Company. The public offering price of the shares was $4.00 per share, and the Underwriter agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $3.68 per share. After the underwriting discount, offering and other related expenses, the Company received net proceeds from the offering of approximately $9.0 million. Pursuant to the Underwriting Agreement, the Company also granted the Underwriter an option to purchase up to 375,000 additional shares of common stock, or 15% of the number of shares sold in the offering, at a price of $3.68 per share, for a period of 30 days from the date of the Underwriting Agreement, of which none were exercised.

Pursuant to the Underwriting Agreement, the Company issued to the Underwriter or its designees warrants to purchase up to an aggregate 125,000 shares of common stock, or 5% of the number of shares sold in the offering (the “Underwriter Warrants”). The Underwriter Warrants are exercisable following the date of issuance, July 7, 2021 and ending five years from the date of the execution of the Underwriting Agreement, July 2, 2026, at a price per share equal to $4.80 per share (120% of the public offering price per share) and are exercisable on a “cashless” basis.

Open Market Sale Agreement

On August 28, 2020, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Jefferies LLC to act as the Company’s sales agent and/or principal (“Jefferies” or the “Agent”), with respect to the issuance and sale of up to $45.0 million of the Company’s shares of common stock ~~(the “Shares”)~~ from time to time in an at-the-market offering.

Upon delivery of a placement notice and subject to the terms and conditions of the Sales Agreement, Jefferies may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. The Company may sell the common stock in amounts and at times to be determined by the Company from time to time subject to the terms and conditions of the Sales Agreement, but it has no obligation to sell any of the ~~Shares~~shares under the Sales Agreement. The Company or Jefferies may suspend or terminate the offering of ~~Shares~~shares upon notice to the other party and subject to other conditions. Jefferies will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq.

The Company paid Agent a commission equal to 3.0% of the gross proceeds from the sale of the ~~Shares~~shares pursuant to the Sales Agreement. The Company has also agreed to provide Jefferies with customary indemnification and contribution rights.

The offering of ~~Shares~~shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all common stock subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms.

The common stock was sold and issued pursuant the Company’s shelf registration statement on Form S-3 (File No. 333-230448), which was previously declared effective by the Securities and Exchange Commission, and a related prospectus.

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

From January 15, 2021 through February 16, 2021, the Company sold 251,720 shares of its common stock through the Open Market Sales Agreement for net proceeds of $1,300,135, after transactional costs of $40,365.

NOTE 9 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

BioSig Technologies, Inc.

2012 Equity Incentive Plan

On October 19, 2012, the Board of Directors of BioSig Technologies, Inc. approved the 2012 Equity Incentive Plan ~~(“the~~(the “Plan”) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan (as amended) provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to ~~11,974,450 (as amended)~~14,474,450 shares of the Company’s common stock to officers, directors, employees and consultants of the Company. Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company or a committee thereof administers the Plan and determines the exercise price, vesting and expiration period of the grants under the Plan.

~~Table of Contents~~

~~BIOSIG TECHNOLOGIES, INC.~~

~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~MARCH 31, 2021~~

~~(unaudited)~~

However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.

Additionally, the vesting period of the grants under the Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. There are ~~1,535,565~~3,606,901 shares remaining available for future issuance of awards under the terms of the Plan as of ~~March 31,~~September 30, 2021.

Options

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees.

For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-based payment awards during the three and nine months ended ~~March 31,~~September 30, 2021 was estimated using the Black-Scholes pricing model.

During the ~~three~~nine months ended ~~March 31,~~September 30, 2021, the Company granted an aggregate of ~~489,500~~917,000 options to officers, directors and key consultants.

~~The following table presents information related to stock options at March 31, 2021:~~

Options Outstanding

Options Exercisable

Weighted

Average

Exercisable

Exercise

Number of

Remaining Life

Number of

Price

Options

In Years

Options

$ 2.51-5.00 2,187,257 8.1 1,499,428
5.01-7.50 1,324,447 6.3 980,179
7.51-10.00 203,333 8.5 100,273
10.01-12.50 65,000 9.1 46,249
3,780,037 7.5 2,626,129

~~A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2021 is as follows:~~

Weighted-Average

Weighted-Average

Remaining

Aggregate

Shares

Exercise Price

Contractual Term

Intrinsic Value

Outstanding at December 31, 2020
3,568,497 $ 5.59 7.0 $ 110,961
Grants
489,500 4.38 10.0 $ -
Exercised
(9,375
)
$ 2.96 -
Forfeited/expired
(268,585
)
$ 7.53 -
Outstanding at March 31, 2021
3,780,037 $ 5.31 7.50 $ 308,891
Exercisable at March 31, 2021
2,626,129 $ 5.34 6.77 $ 228,066

1820

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

The following table presents information related to stock options at September 30, 2021:

Options Outstanding						Options Exercisable
				Weighted
				Average		Exercisable
Exercise		Number of		Remaining Life		Number of
Price		Options		In Years		Options
$	2.51-5.00		2,539,757		7.2		1,579,427
	5.01-7.50		1,229,032		4.7		997,757
	7.51-10.00		203,333		8.0		138,326
	10.01-12.50		65,000		8.6		50,415
			4,037,122		6.5		2,765,925

A summary of the stock option activity and related information for the Plan for the nine months ended September 30, 2021 is as follows:

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2020		3,568,497		$	5.59		7.0	$	110,961
Grants		917,000			3.39		10.0	$	-
Exercised		(9,375	)	$	2.96				-
Forfeited/expired		(439,000	)	$	6.68				-
Outstanding at September 30, 2021		4,037,122		$	5.20		6.5	$	938
Exercisable at September 30, 2021		2,765,925		$	5.35		5.3	$	563

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of BioSig Technologies, Inc. of ~~$4.31~~$2.98 as of ~~March 31,~~September 30, 2021, which would have been received by the option holders had those option holders exercised their options as of that date.

On January 12, 2021, BioSig Technologies, Inc. granted 387,500 options to purchase the company stock in connection with the services rendered at the exercise price of $4.23 per share for a term of ten years with one-third vesting on the ~~one year~~one-year anniversary and two-thirds vesting quarterly thereafter beginning January 12, 2022 for two years.

On February 16, 2021, BioSig Technologies, Inc. granted 102,000 options to purchase the company stock in connection with the services rendered at the exercise price of $4.97 per share for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning February 16, 2022 for two years.

On April 9, 2021, BioSig Technologies, Inc. granted 90,000 options to purchase the company stock in connection with the services rendered at the exercise price of $4.38 per share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 9, 2022 for two years.

On April 13, 2021, BioSig Technologies, Inc. granted 25,000 options to purchase the company stock in connection with the services rendered at the exercise price of $4.42 per share for a term of ten years with one-third vesting on the one-year anniversary and two-thirds vesting quarterly thereafter beginning April 13, 2022 for two years.

On May 18, 2021, BioSig Technologies, Inc. granted 150,000 options to purchase the company stock in connection with the services rendered at the exercise price of $3.20 per share for a term of ten years with one-third vesting on the one year anniversary and two-thirds vesting quarterly thereafter beginning May 18, 2022 for two years.

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

On August 3, 2021, BioSig Technologies, Inc. granted an aggregated of 75,000 options to purchase shares of its common stock to 3 employees. The options are exercisable at $3.61 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years.

On August 31, 2021, BioSig Technologies, Inc. granted an aggregated of 47,500 options to purchase shares of its common stock to 3 employees. The options are exercisable at $2.98 per share for ten years with immediate vesting.

On September 17, 2021, BioSig Technologies, Inc. granted an aggregated of 40,000 options to purchase shares of its common stock to 2 employees. The options are exercisable at $2.99 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years.

The following assumptions were used in determining the fair value of options during the ~~three~~nine months ended ~~March 31,~~September 30, 2021:

Risk-free interest rate		0.83% - 0.94	%		0.77% - 1.30	%
Dividend yield		0	%		0	%
Stock price volatility		94.06% to 95.98	%		83.70% to 95.98	%
Expected life	6 years			5 to 6 years
Weighted average grant date fair value	$	4.03		$	3.39

On June 28, 2021, in connection with the exit of two members of the Company’s board of directors, the Company extended the life of 145,000 previously issued director options from the contractual 90 days from termination of service to the earlier of the initial life or June 28, 2023. The change in estimated fair value of the modified options of $182,514 was charged to current period operations.

The following assumptions were used in determining the change in fair value of the modified options at June 28, 2021:

Risk-free interest rate		0.05% - 0.25	%
Dividend yield		0	%
Stock price volatility		88.57	%
Expected life	0.25 – 2 years

On June 30, 2021, in connection with the resignation of a member of the Company’s board of directors, the Company entered into a one-year consulting contract and extended the life of 221,240 previously issued director options from the contractual 90 days from termination of service to the earlier of the initial life or two years after service contract completion. The change in estimated fair value of the modified options of $111,402 was charged to current period operations.

The following assumptions were used in determining the change in fair value of the modified options on June 30, 2021:

Risk-free interest rate		0.06% - 0.46	%
Dividend yield		0	%
Stock price volatility		88.59	%
Expected life	0.59 – 3 years

The fair value of all options vesting during the three and nine months ended ~~March 31,~~September 30, 2021 of $759,931 and ~~2020 of $576,885~~$1,950,623 and ~~$623,693,~~$483,110 and $4,734,983 for the three and nine months ended September 30, 2020, respectively, was charged to current period operations. Unrecognized compensation expense of ~~$4,349,976~~$3,720,260 at ~~March 31,~~September 30, 2021 will be expensed in future periods.

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

Warrants

The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig Technologies, Inc. at ~~March 31,~~September 30, 2021:

Exercise

Number

Expiration
Price

Outstanding

Date
$ 4.38 548,938
April 2021
$ 4.80 125,000
February 2025
$ 6.16 568,910
November 2027
$ 6.85 193,352
July 2021 to August 2021
1,436,200

Exercise		Number		Expiration
Price		Outstanding		Date
$	4.80		250,000	February 2025 to July 2026
$	6.16		568,910	November 2027
			818,910

On July 7, 2021, BioSig Technologies, Inc. issued warrants to purchase 125,000 shares of its common stock at $4.80 per share, expiring on July 2, 2026, for placement agent services in connection with the sale of the company’s common stock.

A summary of the warrant activity for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 is as follows:

Weighted-Average

Weighted-Average

Remaining
Contractual

Aggregate

Shares

Exercise Price

Term

Intrinsic Value

Outstanding at December 31, 2020
1,446,200 $ 5.44 3.3 $ 1,500
Grants
-
Exercised
-
Expired
(10,000
)
$ 3.75 - -
Outstanding at March 31, 2021
1,436,200 $ 5.45 3.1 $ -

Vested and expected to vest at March 31, 2021
1,436,200 $ 5.45 3.1 $ -
Exercisable at March 31, 2021
1,436,200 $ 5.45 3.1 $ -

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at December 31, 2020		1,446,200		$	5.44		3.3	$	1,500
Grants		125,000		$	4.80		5.0
Expired		(752,290	)	$	5.00		-		-
Outstanding at September 30, 2021		818,910		$	5.74		5.5	$	-

Vested and expected to vest at September 30, 2021		818,910		$	5.74		5.5	$	-
Exercisable at September 30, 2021		818,910		$	5.74		5.5	$	-

~~Table of Contents~~

~~BIOSIG TECHNOLOGIES, INC.~~

~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~MARCH 31, 2021~~

~~(unaudited)~~

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the company’s stock price of ~~$4.31~~$2.98 of ~~March 31,~~September 30, 2021, which would have been received by the option holders had those option holders exercised their options as of that date.

Restricted Stock Units

The following table summarizes the restricted stock activity for the ~~three~~nine months ended ~~March 31,~~September 30, 2021:

Restricted shares issued as of December 31, 2020	218,334
Granted	~~251,000~~301,000
Vested and issued	(~~23,334~~216,834	)
Forfeited	(~~100,000~~120,000	)
Total	182,500

Comprised of:
Vested restricted shares as of ~~March 31,~~September 30, 2021	0-
Unvested restricted shares as of ~~March 31,~~September 30, 2021	~~346,000~~182,500
Total	182,500

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

On January 4, 2021, the Company granted 220,000 restricted stock units for services with 105,000 vesting one-third on the one-year anniversary and two-thirds vesting quarterly thereafter beginning January 4, 2022 for two years and with 115,000 vesting quarterly for one year.

On March 8, 2021 the Company granted 31,000 restricted stock units for services vesting on August 31, 2021.

On June 1, 2021, in connection with the termination of an employee, the Company accelerated vesting of 30,000 previously granted restricted stock units from a three-year period to fully vested. The change in vesting of the modified restricted stock unit resulted in a $109,725 charge to current period operations.

On June 30, 2021, in connection with the resignation of a member of the Company’s board of directors, the Company accelerated vesting of 50,000 previously granted restricted stock units from a three-year period to fully vested. The change in vesting of the modified restricted stock unit resulted in a $232,375 charge to current period operations.

On August 14, 2021 the Company granted 50,000 restricted stock units for services vesting quarterly for one year.

Stock based compensation expense related to restricted stock grants was ~~$99,120~~$63,266 and ~~$401,478~~$773,381 for the three and nine months ended ~~March 31,~~September 30, 2021 and $174,945 and $1,005,243 for the three and nine months ended September 30, 2020, respectively. As of ~~March 31,~~September 30, 2021, the stock-based compensation relating to restricted stock of ~~$1,128,853~~$463,317 remains unamortized.

ViralClear Pharmaceuticals, Inc.

2019 Long-Term Incentive Plan

On September 24, 2019, ViralClear’s Board of Directors approved the 2019 Long-Term Incentive Plan (as subsequently amended, the “ViralClear Plan”). The ViralClear Plan was approved by BioSig as ViralClear’s majority stockholder. The ViralClear Plan provides for the issuance of options, stock appreciation rights, restricted stock and restricted stock units to purchase up to 4,000,000 shares of ViralClear’s common stock to officers, directors, employees and consultants of the ViralClear. Under the terms of the ViralClear Plan, ViralClear may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of ViralClear only and nonstatutory options. The Board of Directors of ViralClear or a committee thereof administers the ViralClear Plan and determines the exercise price, vesting and expiration period of the grants under the ViralClear Plan.

However, the exercise price of an Incentive Stock Option should not be less than 110% of fair market value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair market value for a grantee who is not 10% stockholder. The fair market value of the common stock is determined based on the quoted market price or in absence of such quoted market price, by the administrator in good faith.

Additionally, the vesting period of the grants under the ViralClear Plan will be determined by the administrator, in its sole discretion, with an expiration period of not more than ten years. There are ~~1,987,000~~2,330,750 shares remaining available for future issuance of awards under the terms of the ViralClear Plan.

2024

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

ViralClear Options

A summary of the stock option activity and related information for the ViralClear Plan for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 is as follows:

						Weighted-Average
				Weighted-Average		Remaining Contractual
	Shares			Exercise Price		Term		Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term
Outstanding at December 31, 2020		1,527,666		$	5.00		3.96		1,527,666		$	5.00		3.96
Grants		-							-
Exercised		0							(550,000	)	$	5.00
Forfeited/expired		(852,666	)	$	5.00				(852,666	)	$	5.00
Outstanding at March 31, 2021		675,000		$	5.00		8.61
Exercisable at March 31, 2021		608,332		$	5.00		8.57
Outstanding at September 30, 2021									125,000		$	5.00		7.40
Exercisable at September 30, 2021									74,998		$	5.00		6.62

The following table presents information related to stock options at ~~March 31,~~September 30, 2021:

Options Outstanding

Options Exercisable

Options Outstanding

Options Exercisable

Weighted

Average

Exercisable

Average

Exercisable

Exercise

Number of

Remaining Life

Number of

Exercise

Number of

Remaining Life

Number of

Price

Options

In Years

Options

Price

Options

In Years

Options

5.00

675,000

8.61

608,332

5.00

125,000

6.12

74,998

The fair value of the stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities with the market value of stock price based on recent sales. The Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.

On July 1, 2021, ViralClear issued 206,250 shares of its common stock in exchange for the cashless exercise of 550,000 options previously granted on October 16, 2019.

On June 30, 2021, in connection with the resignation of a member of the Company’s board of directors, the Company entered into a one-year consulting contract and extended the life of 25,000 previously issued director options from the contractual 90 days from termination of service to the earlier of the initial life or two years after service contract completion. The change in estimated fair value of the modified options of $26,577 was charged to current period operations.

The following assumptions were used in determining the change in fair value of the modified options at June 30, 2021:

Risk-free interest rate		0.07% - 0.46	%
Dividend yield		0	%
Stock price volatility		88.59	%
Expected life	1.25 - 3 years

The fair value of all options vesting during the three and nine months ended ~~March 31,~~September 30, 2021 ~~and 2020~~ of $36,521 and ~~$0,~~$109,562 and $242,703 and $5,836,855 for the three and nine months ended September 30, 2020, respectively, was charged to current period operations. Unrecognized compensation expense of ~~$292,166~~$219,124 at ~~March 31,~~September 30, 2021 will be expensed in future periods.

~~Warrants (ViralClear)~~

~~The following table presents information related to warrants (ViralClear) at March 31, 2021:~~

Exercise

Number

Expiration
Price

Outstanding

Date
$ 5.00 473,772
November 2027
10.00 6,575
May 2025
480,347

2125

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

Warrants (ViralClear)

The following table presents information related to warrants (ViralClear) at September 30, 2021:

Exercise		Number		Expiration
Price		Outstanding		Date
$	5.00		473,772	November 2027
	10.00		6,575	May 2025
			480,347

Restricted stock units (ViralClear)

The following table summarizes the restricted stock activity for the ~~three~~nine months ended ~~March 31,~~September 30, 2021:

Restricted shares issued as of December 31, 2020	1,420,716
Granted	-
Issued	(40,000	)
Forfeited	(82,716	)
Total	~~1,338,000~~1,298,000

Comprised of:
Vested restricted shares as of ~~March 31,~~September 30, 2021	~~698,000~~658,000
Unvested restricted shares as of ~~March 31,~~September 30, 2021	640,000
Total	1,298,000

Stock based compensation expense related to restricted stock unit grants of ViralClear was ~~$29,151~~$87,865 and ~~$3,387,413~~$508,896 for the three and nine months ended ~~March 31,~~September 30, 2021 and $485,352 and $5,445,346 for the three and nine months ended September 30, 2020, respectively. As of ~~March 31,~~September 30, 2021, the stock-based compensation relating to restricted stock of ~~$851,839~~$372,093 remains unamortized.

NOTE 10 – NON-CONTROLLING INTEREST

On November 7, 2018, the Company formed ~~ViralClear Pharmaceuticals, Inc.,~~ a ~~Delaware Corporation, formerly~~subsidiary, now known as ~~NeuroClear Technologies, Inc. for the purpose~~ViralClear, to pursue additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology, and subsequently in 2020, was repurposed to develop merimepodib, a broad-spectrum anti-viral agent that ~~had~~showed potential ~~against~~for the ~~COVID-19 virus. In~~treatment of COVID-19. Since late 2020, ViralClear ~~again was repurposed back to~~has been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology.

As of ~~March 31,~~September 30, 2021 and December 31, 2020, the Company had a majority interest in ViralClear of ~~70.2%.~~68.44% and 70.21%, respectively.

A reconciliation of the ViralClear Pharmaceuticals, Inc. non-controlling loss attributable to the Company:

Net ~~loss~~profit attributable to the non-controlling interest for the three months ended ~~March 31, 2021:~~September 30, 2021 (000’s):

Net loss
$ (804,642
)
Average Non-controlling interest percentage of profit/losses
29.8
%
Net loss attributable to the non-controlling interest
$ (239,421
)

Net Income	$	19
Average Non-controlling interest percentage of profit/losses		31.6	%
Net income attributable to the non-controlling interest	$	6

Net loss attributable to the non-controlling interest for the three months ended ~~March 31, 2020:~~September 30, 2020 (000’s):

Net loss	$	(7,621,328	)	$	(5,540	)
Average Non-controlling interest percentage of profit/losses		18.7	%		30.6	%
Net loss attributable to the non-controlling interest	$	(1,427,813	)	$	(1,696	)

~~The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2021:~~

Balance, December 31, 2020
$ 802,269
Allocation of equity to non-controlling interest due to equity-based compensation issued
19,540
Net loss attributable to non-controlling interest
(239,421
)
Balance, March 31, 2021
$ 582,388

2226

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

Net loss attributable to the non-controlling interest for the nine months ended September 30, 2021 (000’s):

Net loss	$	(1,953	)
Average Non-controlling interest percentage of profit/losses		29.9	%
Net loss attributable to the non-controlling interest	$	(584	)

Net loss attributable to the non-controlling interest for the nine months ended September 30, 2020 (000’s):

Net loss	$	(26,272	)
Average Non-controlling interest percentage of profit/losses		23.9	%
Net loss attributable to the non-controlling interest	$	(6,282	)

The following table summarizes the changes in non-controlling interest for the nine months ended September 30, 2021 (000’s):

Balance, December 31, 2020	$	802
Allocation of equity to non-controlling interest due to equity-based compensation issued		220
Net loss attributable to non-controlling interest		(584	)
Balance, September 30, 2021	$	438

NOTE 11 —– COMMITMENTS AND CONTINGENCIES

Licensing agreements

2017 Know-How License Agreement

On March 15, 2017, the Company entered into a know-how license agreement with Mayo Foundation for Medical Education and Research whereby the Company was granted an exclusive license, with the right to sublicense, certain know how and patent applications in the field of signal processing, physiologic recording, electrophysiology recording, electrophysiology software and autonomics to develop, make and offer for sale. The agreement expires in ten years from the effective date.

The Company is obligated to pay to Mayo Foundation a 1% or 2% royalty payment on net sales of licensed products, as defined.

Patent and Know-How License Agreement – EP Software Agreement

On November 20, 2019, the Company entered into a patent and know-how license agreement (the “EP Software Agreement”) with Mayo Foundation for Medical Education and Research (“Mayo”). The EP Software Agreement grants to the Company an exclusive worldwide license, with the right to sublicense, within the field of electrophysiology software and under certain patent rights as described in the EP Software Agreement (the “Patent Rights”), to make, have made, use, offer for sale, sell and import licensed products and a non-exclusive license to the Company to use the research and development information, materials, technical data, unpatented inventions, trade secrets, know-how and supportive information of Mayo to develop, make, have made, use, offer for sale, sell, and import licensed products. The EP Software Agreement will expire upon the later of either (a) the expiration of the Patent Rights or (b) the 10th anniversary of the date of the first commercial sale of a licensed product, unless earlier terminated by Mayo for the Company’s failure to cure a material breach of the EP Software Agreement, the Company’s or a sublicensee’s commencement of any action or proceedings against Mayo or its affiliates other than for an uncured material breach of the EP Software Agreement by Mayo, or insolvency of the Company.

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

In connection with the EP Software Agreement, the Company issued to Mayo an 8-year warrant (the “EP Software Warrant”) to purchase 284,455 shares of the Company’s common stock at an exercise price of $6.16. The EP Software Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement registering or a current prospectus available for the resale of the shares underlying the EP Software Warrant. The Company agreed to pay Mayo an upfront consideration of $25,000. The Company also agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $625,000 in aggregate.

Amended and Restated Patent and Know-How License Agreement – Tools Agreement

On November 20, 2019, the Company entered into an amended and restated patent and know-how license agreement (the “Tools Agreement”) with Mayo. The Tools Agreement contains terms of license grant substantially identical to the EP Software Agreement, although it is for different patent rights and covers the field of electrophysiology systems.

In connection with the Tools Agreement, the Company issued to Mayo an 8-year warrant (the “Tools Warrant”) to purchase 284,455 shares of the Company’s common stock at an exercise price of $6.16. The Tools Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement registering or a current prospectus available for the resale of the shares underlying the Tools Warrant. The Company agreed to pay Mayo an upfront consideration of $100,000. The Company also agreed to make earned royalty payments to Mayo in connection with the Company’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $550,000 in aggregate. In June 2021, patent rights were issued (“Valid Claim”) as defined whereby the Company paid milestone one of $75,000.

ViralClear Patent and Know-How License Agreement

On November 20, 2019, the Company’s majority-owned subsidiary, ViralClear, entered into a patent and know-how license agreement (the “ViralClear Agreement”) with Mayo. The ViralClear Agreement contains terms of license grant substantially identical to the EP Software Agreement and the Tools Agreement, although it is for different patent rights and covers the field of stimulation and electroporation for hypotension/syncope management, renal and non-renal denervation for hypertension treatment, and for use in treatment of arrhythmias in the autonomic nervous system.

~~Table of Contents~~

~~BIOSIG TECHNOLOGIES, INC.~~

~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~MARCH 31, 2021~~

~~(unaudited)~~

In connection with the ViralClear Agreement, ~~NeuroClear~~ViralClear issued to Mayo an 8-year warrant (the “ViralClear Warrant”) to purchase 473,772 shares of ViralClear’s common stock at an exercise price of $5.00 per share. The ViralClear Warrant is immediately exercisable and may be exercised on a cashless basis if there is no effective registration statement registering or a current prospectus available for the resale of the shares underlying the ViralClear Warrant. ViralClear agreed to pay Mayo an upfront consideration of $50,000. ViralClear also agreed to make earned royalty payments to Mayo in connection with ViralClear’s sales of the licensed products to third parties and sublicense income received by the Company and to make milestone payments of up to $700,000 in aggregate. In June 2021, patent rights were issued (“Valid Claim”) as defined whereby the Company paid milestone one of $75,000.

Trek Therapeutics, PBC

In the event of sublicensing, sale, transfer, assignment or similar transaction, ViralClear agreed to pay Trek 10% of the consideration received.

As part of the acquired assets, ViralClear received an assignment and licensing rights agreement from Trek with a third-party vendor regarding certain formulas and compounds usage. The agreement calls for milestone payments upon marketing authorization (as amended and defined with respect of product in a particular jurisdiction in the territory, the receipt of all approvals from the relevant regulatory authority necessary to market and sell such product in any such jurisdiction, excluding any pricing approval or reimbursement authorization) in any first and second country of $10 million and $5 million, respectively, in addition to 6% royalty payments.

~~3LP Advisors LLC (d/b/a Sherpa Technology Group)~~

Table of Contents

BIOSIG TECHNOLOGIES, INC.

On November 1, 2017, in connection with Mr. Filler joining the Company’s Board of Directors, the Company entered into a Master Services Agreement with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing. In connection with the SOW, the Company paid Sherpa fee of (i) $200,000 in cash, of which $25,000 will be paid on January 1, 2018, with the remainder paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 120,000 of the Company’s common stock at an exercise of $3.75 per share of common stock, of which 60,000 options vest immediately and 60,000 options were performance conditioned and subsequently vested. The SOW has been extended throughNOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021 ~~at a monthly rate of $15,000 per month. Mr. Filler is the general counsel and partner of Sherpa.~~

(unaudited)

During the three months ended March 31, 2021 and 2020, the Company paid $45,000 and $104,363 as patent costs, consulting fees and expense reimbursements. As of March 31, 2021 and December 31, 2020, there was an unpaid balance of $15,000 and $15,000, respectively.

Defined Contribution Plan

Effective January 1, 2019, the Company established a qualified defined contribution plan (the “401(k) Plan”) pursuant to Section 401(k) of the Code, whereby all eligible employees may participate. Participants may elect to defer a percentage of their annual pretax compensation to the 401(k) plan, subject to defined limitations. The Company is required to make contributions to the 401(k) Plan equal to 3 percent of each participant’s eligible compensation, subject to limitations under the Code. For the three and nine months ended ~~March 31,~~September 30, 2021, ~~and 2020,~~ the Company charged operations ~~$71,465~~$61,313 and ~~$38,201~~$189,740 and $49,342 and $131,025 for the three and nine months ended September 30, 2020, respectively, for contributions under the 401(k) Plan.

Purchase commitments

As of ~~March 31,~~September 30, 2021, the Company had aggregate purchase commitments of approximately ~~$2,920,830~~$1,959,546 for future services or products, some of which are subject to modification or cancellations.

~~Table of Contents~~

~~BIOSIG TECHNOLOGIES, INC.~~

~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~MARCH 31, 2021~~

~~(unaudited)~~

Litigation

Aurigene Pharmaceutical Services LTD vs. ViralClear Pharmaceuticals Inc. and BioSig Technologies, Inc.

On January 8, 2021, Aurigene Pharmaceutical Services, LTD (“Aurigene”) filed a complaint with the United States District Court for the District of Connecticut claiming the Company is in default of certain milestone payments for manufacturing and services under contracts dated June 23, 2020 and July 16, 2020 in aggregate amount of $1,530,000. ~~The~~

On September 23, 2021, the Company ~~contends that it is not~~entered into a ~~proper party to~~settlement agreement with Aurigene for a sum of $1,000,000 payable in three installments of $400,000, $300,000, and $300,000 on September 30, 2021, December 31, 2021 and March 31, 2022, respectively, with no admission or concession by either party.

In connection with the ~~lawsuit since~~settlement, the ~~agreements at issue were signed by a subsidiary. The~~ Company ~~also contends that Aurigene is not entitled to~~recognized $553,000 gain on settlement of debt in the ~~relief it seeks, because it did not meet its own obligations under~~current period operations as the ~~contracts, including several manufacturing milestones. The Company intends to defend itself vigorously.~~full amount was previously accrued.

The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

NOTE 12 —– SEGMENT REPORTING

In accordance with ASC 280-10, the Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments. The Company has ~~three~~3 reportable segments: BioSig Technologies, Inc. (parent), NeuroClear Technologies, Inc. and ViralClear Pharmaceuticals, Inc.

~~Information concerning the operations of the Company’s reportable segments is as follows:~~

~~Summary Unaudited condensed consolidated Statement of Operations for the 3 months ended March 31, 2021:~~

BioSig
Technologies, Inc.

ViralClear
Pharmaceuticals, Inc.

NeuroClear
Technologies,
Inc.

Total

Revenue:

Product sales
$ 115,367 $ 0 $ 0 $ 115,367
Service
2,680 0 0 2,680
Total Revenue
118,047 0 0 118,047

Cost of goods sold
98,618 0 0 98,618

Gross profit
19,429 0 0 19,429

Operating expenses:

Research and development
1,275,993 (10,286
)
0 1,265,707
General and administrative
6,456,625 814,386 450 7,271,461
Depreciation and amortization
40,728 857 0 41,585
Total operating expenses
7,773,346 804,957 450 8,578,753

Loss from operations
(7,753,917
)
(804,957
)
(450
)
(8,559,324
)

Other income:

Interest income and other income, net
606 114 0 720

Net loss
$ (7,753,311
)
$ (804,843
)
$ (450
)
$ (8,558,604
)

2529

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

~~MARCH 31,~~SEPTEMBER 30, 2021

(unaudited)

Information concerning the operations of the Company’s reportable segments is as follows:

Summary unaudited condensed consolidated Statement of Operations for the three months ended September 30, 2021 (000’s):

	BioSig Technologies, Inc.			ViralClear Pharmaceuticals, Inc.			NeuroClear Technologies, Inc.			Total
Revenue:
Product sales	$	100		$	-		$	-		$	100
Service		8			-			-			8
Total revenue		108			-			-			108

Cost of goods sold		38			-			-			38

Gross profit		70			-			-			70

Operating expenses:
Research and development		1,311			4			-			1,315
General and administrative		5,975			529			1			6,505
Depreciation and amortization		50			1			-			51
Total operating expenses		7,336			534			1			7,871

Loss from operations		(7,266	)		(534	)		(1	)		(7,801	)

Other income:
Interest income and other income, net		1			-			-			1
Gain on settlement of debt		-			553			-			553

Net loss	$	(7,265	)	$	19		$	(1	)	$	(7,247	)

Summary unaudited condensed consolidated Statement of Operations for the three months ended September 30, 2020 (000’s):

	BioSig Technologies, Inc.			ViralClear Pharmaceuticals, Inc.			NeuroClear Technologies, Inc.			Total
Operating expenses:
Research and development	$	698		$	4,183		$	30		$	4,911
General and administrative		6,807			1,358			-			8,165
Depreciation and amortization		24			-			-			24
Total operating expenses		7,529			5,541			30			13,100

Loss from operations		(7,529	)		(5,541	)		(30	)		(13,100	)

Other income:
Interest income and other income, net		2			-			-			2

Net loss	$	(7,527	)	$	(5,541	)	$	(30	)	$	(13,098	)

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

Summary ~~Unaudited~~unaudited condensed consolidated Statement of Operations for the ~~three~~nine months ended ~~March 31, 2020:~~September 30, 2021 (000’s):

												BioSig Technologies, Inc.			ViralClear Pharmaceuticals, Inc.			NeuroClear Technologies, Inc.			Total
Revenue:
Product sales												$	414		$	-		$	-		$	414
Service													19			-			-			19
Total revenue													433			-			-			433

Cost of goods sold													199			-			-			199

Gross profit													234			-			-			234
	BioSig Technologies, Inc.			ViralClear Pharmaceuticals, Inc.			NeuroClear Technologies, Inc.		Total
Operating expenses:
Research and development	$	1,327,003		$	3,599,711		$	0	$	4,926,714			4,042			206			-			4,248
General and administrative		3,819,438			4,035,782			0		7,855,220			17,954			2,297			5			20,256
Depreciation and amortization		21,015			0			0		21,015			139			3			-			142
Total operating expenses		5,167,456			7,635,493			0		12,802,949			22,135			2,506			5			24,646

Loss from operations		(5,167,456	)		(7,635,493	)		0		(12,802,949	)		(21,901	)		(2,506	)		(5	)		(24,412	)

Other income:
Interest income and other income, net		25,411			14,165			0		39,576			2			-			-			2
Gain on settlement of debt													-			553			-			553

Net loss	$	(5,142,045	)	$	(7,621,328	)	$	0	$	(12,763,373	)	$	(21,899	)	$	(1,953	)	$	(5	)	$	(23,857	)

Summary unaudited condensed consolidated Statement of Operations for the nine months ended September 30, 2020 (000’s):

	BioSig Technologies, Inc.			ViralClear Pharmaceuticals, Inc.			NeuroClear Technologies, Inc.			Total
Operating expenses:
Research and development	$	3,112		$	12,414		$	30		$	15,556
General and administrative		18,756			13,873			-			32,629
Depreciation and amortization		66			-			1			67
Total operating expenses		21,934			26,287			31			48,252

Loss from operations		(21,934	)		(26,287	)		(31	)		(48,252	)

Other income (expense):
Interest income and other income, net		30			15			-			45
Loss on foreign currency translation		-			(1	)		-			(1	)

Net loss	$	(21,904	)	$	(26,273	)	$	(31	)	$	(48,208	)

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

Summary of assets at ~~March 31, 2021:~~September 30, 2021 (000’s):

	BioSig Technologies, Inc.		ViralClear Pharmaceuticals, Inc.		NeuroClear Technologies, Inc.		Total		BioSig Technologies, Inc.		ViralClear Pharmaceuticals, Inc.		NeuroClear Technologies, Inc.		Total
Cash	$	18,060,472	$	4,414,394	$	0	$	22,474,866	$	15,138	$	2,397	$	-	$	17,535
Accounts receivable										100		-		-		100
Inventory		649,937		0		0		649,937		1,881		-		-		1,881
Employee advances										50		-		-		50
Other current assets		203,757		4,989		0		208,746		431		2		-		433
Total operating assets		18,914,166		4,419,383		0		23,333,549		17,600		2,399		-		19,999

Property and equipment, net		373,684		7,717		0		381,401		551		6		-		557
Right-to-use assets, net		356,266		0		0		356,266		693		-		-		693
Other assets		444,743		0		0		444,743		424		-		-		424

Total assets	$	20,088,859	$	4,427,100	$	0	$	24,515,959	$	19,268	$	2,405	$	-	$	21,673

NOTE 13 – RELATED PARTY TRANSACTIONS

At ~~March 31,~~September 30, 2021 and December 31, 2020, the Company had reimbursable travel, compensation and other related expenses due related parties of ~~$147,000~~$80,000 and $317,000, ~~respectively.~~

On November 1, 2017, in connection with Mr. Filler joining the Company’s Board of Directors, the Company entered into a Master Services Agreement with 3LP Advisors LLC (d/b/a Sherpa Technology Group) (“Sherpa”) and an initial statement of work (the “SOW”), pursuant to which Sherpa will develop, execute and expand the Company’s intellectual property strategy over the course of the next approximately 18 months by evaluating the business and technology landscape in which the Company operates, and charting and executing a strategy of patent filing and licensing. In connection with the SOW, the Company paid Sherpa fee of (i) $200,000 in cash, of which $25,000 was paid on January 1, 2018, with the remainder to be paid upon completion of certain objectives, and (ii) a ten-year option to purchase up to 120,000 of the Company’s common stock at an exercise of $3.75 per share of common stock, of which 60,000 options vest immediately and 60,000 options were performance conditioned and subsequently vested. Mr. Filler is the general counsel and partner of Sherpa.

During the three months ended March 31, 2021 and 2020, the Company paid $45,000 and $75,000 as patent costs, consulting fees and expense reimbursements. As of March 31, 2021 and December 31, 2020, there was an unpaid balance of $15,000 and $15,000, respectively.

On January 5, 2021, the Company issued an aggregate of 450,000 shares of common stock to officers of the Company as part of annual compensation.

~~Table of Contents~~

~~BIOSIG TECHNOLOGIES, INC.~~

~~NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~MARCH 31, 2021~~

~~(unaudited)~~

NOTE 14 – FAIR VALUE MEASUREMENT

The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:

Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.

As of ~~March 31,~~September 30, 2021, and December 31, 2020, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.

Table of Contents

BIOSIG TECHNOLOGIES, INC.

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2021

(unaudited)

As of ~~March 31,~~September 30, 2021, and December 31, 2020, the Company did not have any derivative instruments that were designated as hedges.

There were no derivative and warrant liability as of ~~March 31,~~September 30, 2021 and December 31, 2020.

NOTE 15 – SUBSEQUENT EVENTS

Equity issuances

On ~~April 1,~~October 4, 2021, ~~ViralClear issued 40,000~~the Company granted 50,000 options to purchase shares of its common stock to a new member of the board. The options are exercisable at $2.98 per share for ten years with 50% vesting at date of grant and 50% vesting on the first anniversary of his appointment date, September 20, 2022.

On October 4, 2021, the Company issued 28,750 shares of its common stock for previously issued vested restricted stock units.

On ~~April 5,~~October 29, 2021, ~~BioSig Technologies, Inc. issued 28,750 shares of its common stock for vested restricted stock units.~~

On April 9, 2021, BioSig Technologies, Inc. granted an aggregate of 90,000 options to purchase shares of its common stock to 4 employees. The options are exercisable at $4.38 per share for ten years with one-third vesting on the ~~first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years.~~

On April 13, 2021, BioSig Technologies, Inc. granted 25,000 options to purchase shares of its common stock to an employee. The options are exercisable at $4.42 per share for ten years with one-third vesting on the first anniversary of the date of grant, and the remaining two-thirds vesting in substantially equal quarterly installments over the following two years.

~~On April 28, 2021, BioSig Technologies, Inc. issued 30,000 shares of its common stock to a consultant for services rendered valued at $110,400.~~

~~On April 30, 2021, BioSig Technologies, Inc.~~Company issued an aggregate of ~~6,948~~27,017 shares of its common stock for services.

2733

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis of Financial Condition and Results of Operations includes a number of forward-looking statements that reflect Management’s current views with respect to future events and financial performance. You can identify these statements by forward-looking words such as “may,” “will,” “expect,” “anticipate,” “believe,” “estimate” and “continue,” or similar words. Those statements include statements regarding the intent, belief or current expectations of us and members of our management team as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements.

Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission. Important factors currently known to Management could cause actual results to differ materially from those in forward-looking statements. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions. Factors that could cause differences include, but are not limited to, expected market demand for our products, fluctuations in pricing for materials, and competition.

Business Overview

BioSig Technologies, Inc.

We are a medical technology company that is commercializing our PURE EP™ System which is an advanced signal acquisition and processing platform designed to provide essential diagnostic signals with high clinical value in all types of cardiac catheter ablations.

PURE EP™ is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures, such as environmental lab noise, signal saturation, slow signal recovery, and inaccurate display of fractionated potentials.

Cardiac catheter ablation is a procedure that involves delivery of energy through the tip of a catheter that scars or destroys heart tissue to correct heart rhythm disturbances. In August 2018, we received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) to market our PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP™ System.

PURE EP™ is a signal processing platform that combines advanced hardware and software to address known challenges associated to signal acquisition, to enable electrophysiologists to see more signals and analyze them in real-time. The device aims to minimize noise and artifacts from cardiac recordings and acquire high-fidelity cardiac signals. Improving fidelity of acquired cardiac signals may potentially increase the diagnostic value of these signals, thereby possibly improving accuracy and efficiency of the EP studies and ablation procedures.

Our initial focus is on improving intracardiac signal acquisition and enhancing diagnostic information for catheter ablation procedures for complex arrhythmias like ventricular tachycardia (“VT”), a potentially life-threatening arrhythmia, and atrial fibrillation (“AF”), the most common cardiac arrhythmia associated with a fivefold risk of stroke.

During 2019, we began conducting our first clinical observational patient cases using the PURE EPEP™ System at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas; Prisma Health at Greenville Health System in South Carolina; Indiana University; and Santa Barbara Cottage Hospital in California.

Table of Contents

The initial experience across these early evaluation centers showed that the PURE EP™ System functions as designed: we received positive feedback from the EP users about the improved signal detection and fidelity during ablation procedures on patients with various arrhythmias, such as ischemic ventricular tachycardia, AF, atypical flutter, atrioventricular nodal reentry tachycardia (AVNRT), supraventricular tachycardia, premature ventricular contractions (PVC), and a rare case of dual septal pathway.

~~Table of Contents~~

In November 2019, we commenced our first clinical study for the PURE EP™ System titled, “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study).” Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas, was the first institution to conduct patient cases under the clinical study; Mayo Clinic in Jacksonville, Florida was the second institution; and Massachusetts General Hospital (MGH) was the third to conduct patient cases under the same clinical study. As of March 8, 2021, 81 patients have been enrolled in the study. Initial results of evaluated data from theThe PURE EP 2.0 Study ~~found that a cumulative total of 29 PURE EP signals out of 34 (85.3%) were rated as statistically equivalent or better for the dataset (identical electrocardiographic~~was conducted at three U.S. hospitals: Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and intracardiac signal data recorded during 15 AF ablation procedures from the PURE EP System, the signal recording system, and the 3D mapping system). In 35.5% of samples, the reviewers selected PURE EP because "more signal components were visible." Massachusetts General Hospital.

On April 13, 2021, we announced the completion of the enrollment in the PURE EP 2.0 Study. Intracardiac signal data of clinical interest were collected during 51 cardiac ablation procedures using the PURE EP™ System, the signal recording system, and the 3D mapping system at the same time stamps. The samples were randomized and subjected to blinded, head-to-head evaluation by three independent electrophysiologists to determine the overall quality and clinical utility of PURE EP™ signals when compared to conventional sources. Each reviewer responded to the same 235 signal comparisons using a 10-point rating scale.

Results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP signals over the signals from conventional sources. Further analysis of the responses from the blinded reviewers showed an 83% (p-value <0.001) improved confidence when interpreting complex multi-component signals, leading to a better understanding of the catheter position in relation to the ablation target. Additionally, there was a 73% (p-value <0.001) improved visualization of small, fractionated potentials increasing the proper analysis of scar and abnormal conduction tissue characteristics.

The study manuscript, “Evaluation of a novel cardiac signal processing system for electrophysiology procedures: the PURE EP 2.0 study" has been published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. The manuscript is co-authored by Amin Al-Ahmad, M.D., FHRS, Bradley Knight, M.D., FHRS, Wendy Tzou, M.D., FHRS, Robert Schaller, D.O., FHRS, Omar Yasin, M.D, Deepak Padmanabhan, M.D., Jason Zagrodsky, M.D., FHRS, Mohammed Bassiouny, M.D., J David Burkhardt, M.D., FHRS, Joseph Gallinghouse Jr., M.D., FHRS, Moussa Mansour, M.D., FHRS, Christopher McLeod, MBChB, Ph.D., FHRS and Andrea Natale, M.D., FHRS, the Principal Investigator of the study. The independent, blinded reviewers were Bradley P. Knight, M.D. (Northwestern University), Wendy Tzou, M.D. (University of Colorado), and Robert Schaller, M.D. (University of Pennsylvania).

We continue to install PURE EPEP™ Systems at centers of excellence for clinical evaluation under our market development plan. The PURE EPEP™ System has been utilized at ~~several~~numerous institutions, including the University of Pennsylvania ~~Hospital;~~Hospital in Philadelphia, Pennsylvania; Overland Park Regional Medical System in Overland Park, Kansas; Deborah Heart and Lung Center in Browns Mills, New Jersey; ~~and Memorial Hospital of South Bend, part of Beacon Health System, in South Bend, Indiana; and~~ Houston Methodist in Houston, Texas; and Medical City North Hills in North Richland Hills, Texas.

To date, more than ~~800~~1,600 patient procedures have been conducted with the PURE EP System by more than 4471 electrophysiologists across ~~nine~~thirteen different clinical sites in the United States.

In addition to clinical evaluation, we have conducted ~~a total of twenty-seven~~ pre-clinical ~~studies~~evaluation under several study protocols with the PURE EP™ ~~System, twenty-two of which were performed at~~System. At Mayo Clinic in Rochester, ~~Minnesota. We~~Minnesota, we have performed twenty-five experiments in various animal models; we also conducted a pre-clinical study at the Mount Sinai Hospital in New York, New York, with an emphasis on the VT model; and ~~four pre-clinical studies~~six experiments to date during a study at the University of Pennsylvania. We intend to continue additional research and development studies with our technology at Mayo Clinic and the University of Pennsylvania. ~~We also intend~~

In September 2021, we announced that we entered into a manufacturing and professional services agreement with Plexus Corp (“Plexus”) [Nasdaq: PLXS]. Under the terms of the agreement, Plexus will bring to ~~continue additional clinical external evaluation at~~market the PURE EP™ System and develop a ~~select number~~new product pipeline for our subsidiary, ViralClear Pharmaceuticals, Inc. (“ViralClear”).

Table of ~~other centers.~~

Contents

We have made progress towards obtaining a European CE marking certificate for medical devices. We ~~intend to commence~~have concluded audit preparation for the International Organization for Standardization (“ISO”) 13485 final certification audit with the expectation to proceed with the audit to obtain the ISO 13485 Certification ~~and CE Mark~~ in the first half of ~~2021~~2022 and ~~subsequently file for~~ CE ~~Mark~~Marking in the ~~second~~first half of ~~2021 or early in 2022,~~2023, subject to the guidance and availability from the European ~~notified body.~~Notified Body.

In December 2020, we announced that three ~~units~~PURE EP™ Systems were contracted for purchase by StSt. David’s Healthcare ofin Austin, Texas and were subsequently sold in February 2021. These units were our first commercial sale. ~~On April 6, 2021 we announced the sale of our units~~We also sold three PURE EP™ Systems to ~~multiple campuses of a leading hospital system,~~ Mayo Foundation for Medical Education and ~~Research. Additionally,~~Research in year-to-date 2021 and we are in active discussions with ~~numerous~~several accounts about the acquisition of the PURE EP™ System. We anticipate our initial customers will be medical centers of excellence and other healthcare facilities that operate EP labs.

ViralClear Pharmaceuticals, Inc.

ViralClear Pharmaceuticals, Inc. (“ViralClear”) is a majority-owned subsidiary of the Company originally known as NeuroClear Technologies, Inc. The subsidiary was established November 2018 to pursue additional applications of the PURE EP™ signal processing technology outside of EP. In March 2020, it was renamed ViralClear to develop merimepodib, a broad-spectrum anti-viral agent that showed potential to treat COVID-19. We currently do not intend to further develop merimepodib. Since late 2020, ViralClear has been realigned with its original objective of pursuing additional applications of the PURE EP™ signal processing technology outside of cardiac electrophysiology. As of ~~March 31,~~September 30, 2021, the Company retains ~~70.2%~~68.44% ownership of ViralClear.

~~Recent Developments~~

~~Mayo Clinic Artificial Intelligence (AI) Research Collaboration~~

On January 2, 2021 we entered into a research agreement with Mayo Clinic regarding a Novel AI Program for our Novel Signal Recording System. The program is a strategic collaboration with Mayo to develop a next-generation AI- and machine learning-powered software for our PURE EP™ System. The new collaboration includes an R&D program that is expected to expand our proprietary hardware and software with advanced signal processing capabilities and aim to develop novel technological solutions by combining the electrophysiological signals delivered by PURE EP™ and other data sources.

The development program is under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory, and Alexander D. Wissner-Gross, Ph.D., Managing Director of Reified LLC. We entered into a 10-year collaboration agreement with Mayo Clinic in March 2017 and in November 2019, we signed a patent and know-how license agreement with Mayo Foundation for Medical Education and Research in which such terms apply to this program. We also entered into a partnership with Reified LLC, a provider of advanced artificial intelligence-focused technical advisory services to the private sector in late 2019.

~~Table of Contents~~

Results of Operations (000’s)

We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, such as the progress of our research and development and commercialization efforts, the timing and outcome of future regulatory submissions and uncertainty around the current pandemic. Due to these uncertainties, accurate predictions of future operations are difficult or impossible to make.

Three Months Ended ~~March 31,~~September 30, 2021 Compared to Three Months Ended ~~March 31,~~September 30, 2020 (000’s)

Revenues and Cost of Goods Sold. Revenue for the three months ended ~~March 31,~~September 30, 2021 totaled ~~$118,047~~$108 comprised of product sales of ~~$115,367~~$100 and recognized service revenue of ~~$2,680~~$8 as compared to nil for the three months ended ~~March 31,~~September 30, 2020.

We derive our revenue primarily from the sale of our medical device, PURE EP system, as well as related support and maintenance services and software upgrades in connection with the system.

We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”). The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

Cost of sales for the three months ended ~~March 31,~~September 30, 2021 was ~~$98,518~~$38 comprised of the delivered product as compared to nil for the three months ended ~~March 31,~~September 30, 2020.

Gross profit from the three months ended ~~March 31,~~September 30, 2021 was ~~$19,529~~$70 or 64.8% as compared to nil for the three months ended ~~March 31,~~September 30, 2020.

Research and Development Expenses. Research and development expenses for the three months ended ~~March 31,~~September 30, 2021 were ~~$1,265,507,~~$1,315, a decrease of ~~$3,661,207,~~$3,596, or ~~74.3%~~73.2%, from ~~$4,926,714~~$4,911 for the three months ended ~~March 31,~~September 30, 2020. This decrease is primarily due to ~~acquired~~reduction in research and development ~~cost~~costs incurred during the three months ended ~~March 31,~~September 30, 2020 of ~~$3,524,550~~$4,183 in the ViralClear segment as compared to ~~nil~~$4 for the current period and the ceasing of merimepodib development in 2020, net with an increase in the ~~ViralClear segment.~~BioSig segment research and development from $698 for the three months ended September 30, 2020 to $1,311 for the current period. Research and development expenses were comprised of the following:

Table of Contents

Three months ended:

	March 31, 2021		March 31, 2020		September 30, 2021 (000’s)		September 30, 2020 (000’s)
Salaries and equity compensation	$	498,729	$	892,502	$	751	$	574
Consulting expenses		188,636		271,963		177		805
Research and clinical studies and design work		295,460		166,153		190		1,020
Acquired Research and Development		-		3,524,550		-		(997	)
Data/AI development		126,875		-		84		127
Regulatory		58,646		-		68		1
Product development		14,578		-		-		3,362
Formulation						-		1
Travel, supplies, other		82,583		71,546		45		18
Total	$	1,265,507	$	4,926,714	$	1,315	$	4,911

On September 2, 2020, we entered into an amendment with a third-party assignment and licensing agreement acquired with the asset acquisition from Trek. The amendment eliminated clinical trial milestone payments, leaving only two milestone events and associated payments, and increasing possible royalty payments from 5% to 6%. During the three months ended September 30, 2020, we reversed previously record payment obligations.

Stock based compensation for research and development personnel was ~~$(66,605)~~$371 and ~~$314,303~~$308 for the three months ended ~~March 31,~~September 30, 2021 and ~~2010,~~2020, respectively.

General and Administrative Expenses. General and administrative expenses for the three months ended ~~March 31,~~September 30, 2021 were ~~$7,271,461,~~$6,505, a decrease of ~~$583,759,~~$1,660, or ~~7.4%~~20.3%, from ~~$7,855,220~~$8,165 incurred in the three months ended ~~March 31,~~September 30, 2020. This decrease is primarily due to reduction in the activities of our ViralClear segment, net with an increase in employee performance pay and staff in the current period as compared to the same period in the prior year and additional service provider fees paid.

Payroll related expenses increased to ~~$1,848,821~~$2,134 in the current period from ~~$1,302,971~~$1,621 for the three months ended ~~March 31,~~September 30, 2020, an increase of ~~$545,850~~$513, or ~~41.9%~~31.6%. The increase was primarily due to ~~performance pay and~~ added staff in commercialization, sales and research and development in the ~~later part~~BioSig segment, net with a reduction in 2021 of ~~2020 and 2021 for commercialization and support personnel.~~the ViralClear pharma operations. We incurred ~~$2,585,900~~$1,931 in stock-based compensation in connection with the vesting of stock and stock options issued to board members, officers, employees and consultants for the three months ended ~~March 31,~~September 30, 2021 as compared to ~~$4,098,281~~$4,786 in stock-based compensation for the same period in 2020.

~~Table of Contents~~

Professional services for the three months ended ~~March 31,~~September 30, 2021 totaled ~~$379,504,~~$271, a decrease of ~~$111,668,~~$82, or ~~22.7%~~23.2%, over the ~~$491,172~~$353 recognized for the three months ended ~~March 31,~~September 30, 2020. Of professional services, legal fees totaled ~~$307,779~~$222 for the three months ended ~~March 31,~~September 30, 2021; a decrease of ~~$77,687~~$115, or ~~20.2%~~34.1%, from ~~$385,466~~$337 incurred for the three months ended ~~March 31,~~September 30, 2020. The decrease is primarily due to costs incurred in 2020 for ~~financing.~~financing, contract work and patent filings for the ViralClear segment not incurred in current period. Accounting fees incurred in the three months ended ~~March 31,~~September 30, 2021 amounted to ~~$71,725, a decrease~~$38, an increase of ~~$33,981~~$21, or ~~32.2%~~123.5%, from ~~$105,706~~$17 incurred in same period last year. In ~~2020,~~2021, we incurred ~~additional~~our yearly ViralClear audit ~~costs associated with internal control and ViralClear audits~~ in addition to our ~~yearend~~review requirements.

Consulting, public and investor relations fees for the three months ended ~~March 31,~~September 30, 2021 were ~~$1,374,320~~$1,005 as compared to ~~$1,286,392~~$871 incurred for the three months ended ~~March 31,~~September 30, 2020, an increase of ~~$87,928~~$134, or ~~6.8%~~15.4%. The increase in consulting, marketing and investor relations fees during the three months ended ~~March 31,~~September 30, 2021 related to our continued efforts to develop our recognition throughout the medical industry in an effective manner.

Travel, meals and entertainment costs for the three months ended ~~March 31,~~September 30, 2021 were ~~$108,940, a decrease~~$312, an increase of ~~$94,950,~~$271, or ~~46.6%~~661.0%, from ~~$203,890~~$41 incurred in the three months ended ~~March 31,~~September 30, 2020. Travel, meals and entertainment costs include travel related to business development and financing. The ~~decrease~~increase in 2021 was due to the lifting of various restrictions imposed by the COVID-19 outbreak leading to increased commercialization effort in 2021 as compared to 2020.

Table of Contents

Rent for the three months ended September 30, 2021 totaled $119, a decrease of $5, or 4.0%, from $124 incurred in three months ended September 30, 2020. The decrease in rent for 2021 as compared to 2020 is due primarily to a lower negotiated rent for our Los Angeles offices beginning July 1, 2021 and reduction of our rent in our Connecticut headquarters with our move to a larger facility in September 2021 as compared to 2020.

Depreciation and Amortization Expense. Depreciation and amortization expense for the three months ended September 30, 2021 totaled $51, an increase of $27, or 112.5%, over the expense of $24 incurred in the three months ended September 30, 2020, as a result of the adding additional office computers and other equipment.

Gain on Settlement of Debt. On September 23, 2021 the Company negotiated a lawsuit settlement with Aurigene Pharmaceutical Services LTD relating to certain milestone payments for manufacturing and services under a contract with our ViralClear subsidiary. In connection with the settlement, the Company recognized a gain on settlement of debt of $553 during the three months ended September 30, 2021.

Preferred Stock Dividend. Preferred stock dividend for the three months ended September 30, 2021 and 2020 totaled $2. Preferred stock dividends are related to the dividends accrued on our Series C Preferred Stock issued during the period from 2013 through 2015.

Net Loss Attributable to BioSig Technologies, Inc. Common Shareholders. As a result of the foregoing, net loss attributable to common shareholders for the three months ended September 30, 2021 was $7,255 compared to a net loss of $11,404 for the three months ended September 30, 2020.

Nine Months Ended September 30, 2021 Compared to Nine Months Ended September 30, 2020 (000’s)

Revenues and Cost of Goods Sold. Revenue for the nine months ended September 30, 2021 totaled $433 comprised of product sales of $414 and recognized service revenue of $19 as compared to nil for the nine months ended September 30, 2020.

We derive our revenue primarily from the sale of our medical device, PURE EP system, as well as related support and maintenance services and software upgrades in connection with the system.

Cost of sales for the nine months ended September 30, 2021 was $199 comprised of the delivered product as compared to nil for the nine months ended September 30, 2020.

Gross profit for the nine months ended September 30, 2021 was $234 or 54.0% as compared to nil for the nine months ended September 30, 2020.

Research and Development Expenses. Research and development expenses for the nine months ended September 30, 2021 were $4,248, a decrease of $11,308, or 72.7%, from $15,556 for the nine months ended September 30, 2020. This decrease is primarily due to acquired research and development cost incurred during the nine months ended September 30, 2020 of $12,414 in the ViralClear segment as compared to $206 for the current period and the ceasing of pharma development in 2020. Research and development expenses were comprised of the following:

Table of Contents

Nine months ended:

	September 30, 2021 (000’s)		September 30, 2020 (000’s)
Salaries and equity compensation	$	2,026	$	2,223
Consulting expenses		531		2,069
Research and clinical studies and design work		881		1,505
Acquired Research and Development		150		4,883
Data/AI development		295		379
Regulatory		136		32
Product development		15		4,195
Formulation		-		116
Travel, supplies, other		214		154
Total	$	4,248	$	15,556

Stock based compensation for research and development personnel was $454 and $1,445 for the nine months ended September 30, 2021 and 2020, respectively.

General and Administrative Expenses. General and administrative expenses for the nine months ended September 30, 2021 were $20,256, a decrease of $12,373, or 37.9%, from $32,629 incurred in the nine months ended September 30, 2020. This decrease is primarily due to reduction in the activities of our ViralClear segment, net with an increase in employee performance pay and staff in the current period as compared to the same period in the prior year and additional service provider fees paid.

Payroll related expenses increased to $6,107 in the current period from $5,109 for the nine months ended September 30, 2020, an increase of $998, or 19.5%. The increase was due to performance pay and added staff in the later part of 2020 and 2021 for commercialization, sales and support personnel. We incurred $6,480 in stock-based compensation in connection with the vesting of stock and stock options issued to board members, officers, employees and consultants for the nine months ended September 30, 2021, as compared to $19,678 in stock-based compensation for the same period in 2020.

Professional services for the nine months ended September 30, 2021 totaled $1,035, a decrease of $482, or 31.8%, over the $1,517 recognized for the nine months ended September 30, 2020. Of professional services, legal fees totaled $778 for the nine months ended September 30, 2021; a decrease of $513, or 39.7%, from $1,291 incurred for the nine months ended September 30, 2020. The decrease is primarily due to costs incurred in 2020 for financing a non-consummated capital raise and legal costs incurred in our ViralClear subsidiary. Accounting fees incurred in the nine months ended September 30, 2021 amounted to $149, a decrease of $78 or 34.4%, from $227 incurred in same period last year. In 2020, we incurred additional audit costs associated with internal control and ViralClear audits in addition to our year-end requirements.

Consulting, public and investor relations fees for the nine months ended September 30, 2021 were $3,137 as compared to $3,685 incurred for the nine months ended September 30, 2020, a decrease of $548, or 14.9%. The decrease in consulting, marketing and investor relations fees during the nine months ended September 30, 2021 related to our continued efforts to develop our recognition throughout the medical industry in an effective manner.

Travel, meals and entertainment costs for the nine months ended September 30, 2021 were $730, an increase of $436, or 148.3%, from $294 incurred in the nine months ended September 30, 2020. Travel, meals and entertainment costs include travel related to business development and financing. The increase in 2021 was due to lifting of various restrictions imposed by the COVID-19 outbreak as compared to 2020.

Rent for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 totaled ~~$117,347,~~$353, a decrease of ~~$2,061~~$10, or ~~1.7%~~2.8%, from ~~$119,408~~$363 incurred in ~~three~~nine months ended ~~March 31,~~September 30, 2020. The decrease in rent for 2021 as compared to 2020 is due primarily ~~reduction in warehousing costs in 2021.~~to a lower negotiated rent for our Los Angeles offices beginning July 1, 2021 as compared to 2020.

Table of Contents

Depreciation and Amortization Expense. Depreciation and amortization expense for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 totaled ~~$41,586,~~$142, an increase of ~~$20,571,~~$75, or ~~97.9%~~111.9%, over the expense of ~~$21,015~~$67 incurred in the ~~three~~nine months ended ~~March 31,~~September 30, 2020, as a result of the adding additional office computers and other equipment.

Gain on Settlement of Debt. On September 23, 2021 we negotiated a lawsuit settlement with Aurigene Pharmaceutical Services LTD relating to certain milestone payments for manufacturing and services under a contract with our ViralClear subsidiary. In connection with the settlement, we recognized a gain on settlement of debt of $553 during the nine months ended September 30, 2021.

Preferred Stock Dividend. Preferred stock dividend for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 totaled ~~$2,330,~~$7, a decrease of ~~$2,288,~~$4, or ~~49.5%~~36.4% from ~~$4,618~~$11 incurred during the ~~three~~nine months ended ~~March 31,~~September 30, 2020. Preferred stock dividends are related to the dividends accrued on our Series C Preferred Stock issued during the period from 2013 through 2015. The decrease in 2021 as compared to 2020 is the result of conversions in 2020.

Net Loss ~~available~~Attributable to BioSig Technologies, Inc. ~~common shareholders~~Common Shareholders. As a result of the foregoing, net loss ~~available~~attributable to common shareholders for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 was ~~$8,321,311~~$23,280 compared to a net loss of ~~$11,340,178~~$41,937 for the ~~three~~nine months ended ~~March 31,~~September 30, 2020.

Segment Results

The Company reports segment information based on the “management” approach. The management approach designates the internal reporting used by management for making decisions and assessing performance as the source of the Company’s reportable segments.

Summary Statement of Operations for the three and nine months ended ~~March 31,~~September 30, 2021 as compared to the three and nine months ended ~~March 31,~~September 30, 2020 are detailed in Note 12 of the accompanying unaudited condensed consolidated financial statements.

COVID-19

On March 11, 2020, the World Health Organization (the “WHO”) declared a pandemic related to the rapidly spreading coronavirus (COVID-19) outbreak, which has led to a global health emergency. The full public-health impact of the ongoing pandemic is currently indeterminable and rapidly evolving, and the related health crisis has adversely affected and may continue to adversely affect the global economy, resulting in delaying to our commercialization objectives of the PURE EP Systems into ~~2021.~~2022.

Liquidity and Capital Resources ($000’s)

As of ~~March 31,~~September 30, 2021, we had a working capital of ~~$19,437,887,~~$17,428, comprised of cash of ~~$22,474,866,~~$17,535, accounts receivable of $100, inventory of ~~$649,937~~$1,881 and prepaid expenses, ~~and~~ vendor deposits and employee advances of ~~$208,746,~~$483, which was offset by ~~$3,459,035~~$2,169 of accounts payable and accrued expenses, accrued dividends on preferred stock issuances of ~~$74,547~~$79 and current portions of deferred revenue of ~~$32,156~~$32 and of lease liability of ~~$329,924.~~$291. For the ~~three~~nine months ended ~~March 31,~~September 30, 2021, we used ~~$6,991,172~~$20,668 of cash in operating activities and ~~$129,876~~$398 of cash in investing activities.

~~Table of Contents~~

~~Three~~Nine Months Ended ~~March 31,~~September 30, 2021 Compared to ~~Three~~Nine Months Ended ~~March 31,~~September 30, 2020 (000’s)

Cash provided by financing activities totaled ~~$1,327,885,~~$10,333, comprised of proceeds from the sale of our common stock, net of expenses, of $9,005 and sale of our common stock under ~~our at-the-marketing~~an at-the-market offering of ~~$1,300,135 and~~$1,300 along with proceeds from exercise of options of ~~$27,750.~~$28.

In the comparable period in 2020, our aggregate cash provided by financing activities totaled ~~$9,353,951,~~$41,197, comprised of proceeds from the sale of our common stock of ~~$9,052,331~~$25,214, proceeds from the sale of our common stock in an at-the-market offering of $1,002, proceeds from the sale of our subsidiary common stock of $10,592 and proceeds from exercise of options and warrants of ~~$301,620.~~$4,389. At ~~March 31,~~September 30, 2021, we had cash of ~~$22,474,866~~$17,535 compared to ~~$15,499,734~~$32,748 at ~~March 31,~~September 30, 2020. Our cash is held in bank deposit accounts. At ~~March 31,~~September 30, 2021 and ~~March 31,~~September 30, 2020, we had no convertible debentures outstanding.

Table of Contents

Cash used in operations for the ~~three~~nine months ended ~~March 31,~~September 30, 2021 and 2020 was ~~$6,991,172~~$20,668 and ~~$5,942,321,~~$20,497, respectively, which represent cash outlays for research and development and general and administrative expenses in such periods. The increases in cash outlays principally resulted ~~from~~ additional operating costs, general and administrative expenses ~~net~~in 2021 and with ~~a decrease~~increases in our operating assets of ~~$214,287,~~$1,380 and a decrease in our operating liabilities of ~~$1,318,000 and stock-based compensation and depreciation and amortization.~~$3,393, net with ceasing our ViralClear segment’s pharma operations in 2020.

We used ~~$129,876~~$398 cash for investing activities for the ~~three~~nine months ended ~~March 31,~~September 30, 2021, compared to ~~$20,478~~$60 for the ~~three~~nine months ended ~~March 31,~~September 30, 2020. For the current period and comparable period, we purchased computer and other equipment.

We had an accumulated deficit as of ~~March 31,~~September 30, 2021 of ~~$165.3~~$180.3 million, as well as a net loss attributable to BioSig Technologies, Inc. of ~~$8.3 million~~$23.3 and negative operating cash flows. We expect to continue incurring losses and negative cash flows from operations until our products (primarily PURE EP System) reach full commercial profitability. We believe that our existing cash on hand will be sufficient to enable us to fund our projected operating requirements for approximately one year and a ~~day.~~day from the date of filing of this report. However, we may need to raise additional funds more quickly if one or more of our assumptions prove to be incorrect or if we choose to expand our product development efforts more rapidly than we presently anticipate. We also may decide to raise additional funds before we require them if we are presented with favorable terms for raising capital.

Our plans include the continued commercialization of the PURE EP System and other applications of our core technology and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances, however, that we will be successful in obtaining the level of financing needed for our operations. The ongoing COVID-19 pandemic has resulted and continues to result in significant financial market volatility and uncertainty in recent months.

A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital and on the market price of our common stock, and we may not be able to successfully raise capital through the sale of our securities. ~~If we are unsuccessful in commercializing our products and raising capital, we may need to reduce activities, curtail or cease operations.~~

Our Series C Preferred Stock contains triggering events which would, among other things, require redemption (i) in cash, at the greater of (a) 120% of the stated value of ~~$1,000~~$1 or (b) the product of (I) the variable weighted average price of our common stock on the trading day immediately preceding the date of the triggering event and (II) the stated value divided by the then conversion price or (ii) in shares of our common stock, equal to a number of shares equal to the amount set forth in (i) above divided by 75%. As of ~~March 31,~~September 30, 2021, the aggregate stated value of our Series C Preferred Stock was ~~$105,000.~~$105. The triggering events include our being subject to a judgment of greater than ~~$100,000~~$100 or our initiation of bankruptcy proceedings. If any of the triggering events contained in our Series C Preferred Stock occur, the holders of our Series C Preferred Stock may demand redemption, an obligation we may not have the ability to meet at the time of such demand. We will be required to pay interest on any amounts remaining unpaid after the required redemption of our Series C Preferred Stock, at a rate equal to the lesser of 18% per annum or the maximum rate permitted by applicable law.

We expect to incur losses from operations for the near future. We expect to incur increasing marketing and commercialization expenses related to our PURE EP system in addition to additional research and development costs relating to the PURE EP and other product candidates, including expenses related to clinical trials. We expect that our general and administrative expenses will increase in the future as we expand our business development, add infrastructure and incur additional costs related to being a public company, including incremental audit fees, investor relations programs and increased professional services.

Table of Contents

Our future capital requirements will depend on a number of factors, including the progress of our research and development of product candidates, the timing and outcome of regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights, the status of competitive products, the availability of financing and our success in developing markets for our product candidates.

~~Table of Contents~~

Future financing may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, existing holders of our securities may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our securities.

~~At-the-Market Offering~~Equity Financing

On ~~August 28, 2020,~~July 2, 2021, we entered into an ~~Open Market Sale Agreement~~underwriting agreement (the ~~“Sales~~“Underwriting Agreement”) with ~~Jefferies LLC~~Laidlaw & Company (UK) Ltd. (the “Underwriter”), relating to ~~act as our sales agent and/or principal (“Jefferies” or~~an underwritten public offering of 2,500,000 shares of the ~~“Agent”), with respect~~Company’s common stock, $0.001 par value per share. All of the shares were sold by us. The public offering price of the shares was $4.00 per share, and the Underwriter agreed to purchase the shares from us pursuant to the ~~issuance~~Underwriting Agreement at a price of $3.68 per share. After the underwriting discount, offering and ~~sale~~other related expenses, we received net proceeds from the offering of approximately $9.0 million. Pursuant to the Underwriting Agreement, we also granted the Underwriter an option to purchase up to ~~$45,000,000 of our~~375,000 additional shares of common stock, ~~par value $0.001~~or 15% of the number of Shares sold in the offering, at a price of $3.68 per share, ~~(the “Shares”),~~for a period of 30 days from ~~time to time in an at-the-market offering (the “Offering”).~~the date of the Underwriting Agreement, of which none were exercised.

Upon delivery of a placement notice, Jefferies may sell the Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). We may sell the Shares in amounts and at times to be determined by us from time to time subjectPursuant to the ~~terms and conditions~~Underwriting Agreement, we issued to the Underwriter or its designees warrants to purchase up to an aggregate 125,000 shares of common stock, or 5% of the ~~Sales Agreement, but we have no obligation to sell any~~number of shares sold in the offering (the “Underwriter Warrants”). The Underwriter Warrants are exercisable following the date of issuance, July 7, 2021 and ending five years from the date of the ~~Shares under~~execution of the ~~Sales Agreement. We or Jefferies may suspend or terminate~~Underwriting Agreement, July 2, 2026, at a price per share equal to $4.80 per share (120% of the public offering ~~of Shares upon notice to the other party~~price per share) and ~~subject to other conditions. Jefferies will act as sales agent~~are exercisable on a ~~commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq.~~

We will pay Agent a commission equal to 3.0% of the gross proceeds from the sale of the Shares pursuant to the Sales Agreement. The Company has also agreed to provide Jefferies with customary indemnification and contribution rights.“cashless” basis.

The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Shares subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms.

~~From January 15, 2021 through February 16, 2021, the Company sold 251,720~~ shares ~~of its common stock through the Open Market Sales Agreement for net proceeds of $1,300,135, after transactional costs of $40,365.~~

~~The Shares are~~were sold and issued pursuant ~~the Company’s~~to our shelf registration statement on Form S-3 ~~(File~~(Registration Statement No. ~~333-230448), which was~~333-251859) previously filed with the Securities and Exchange Commission and declared effective by the Securities and Exchange Commission on January 12, 2021. A preliminary prospectus supplement and ~~a related prospectus. On March 25, 2021,~~prospectus supplement and the ~~Sales Agreement was canceled with approximately $41M remaining available under the Shelf registration.~~

On March 25, 2021, the Company delivered written notice to Jefferies to terminate the Sales Agreement effective as of April 8, 2021, pursuant to Section 7(b)(i) thereof. The Company was not subject to any termination penalties relatedaccompanying prospectus relating to the ~~termination of~~offering were filed with the ~~Sales Agreement.~~Securities and Exchange Commission. The offering closed on July 7, 2021.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

Table of Contents

We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our financial statements.

Revenue Recognition

We derive its revenue primarily from the sale of its medical device, the PURE EP™ System, and well as related support and maintenance services and software upgrades in connection with the system.

We determine revenue recognition through the following five steps:

●

Identify the contract with the customer;

●

Identify the performance obligations in the contract;

	●	Determine the transaction price;

	●	Allocate the transaction price to the performance obligation in the contract; and

●

Recognize revenue when, or as, the performance obligations are satisfied.

Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. If we determine that it has not satisfied a performance obligation, it will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Support, maintenance, and software upgrades are performance obligations over a defined period and are recognized ratably over the contractual service period. Customers typically purchase these services with the initial sale of the PURE EP System and do not have the right to terminate their contracts unless we fail to perform material obligations.

We may execute more than one contract with a single customer. If so, it is evaluated whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements.

We record accounts receivable for amounts invoiced to customers for which the Company has an unconditional right to consideration as provided under the contractual arrangement. Unbilled receivables, if any, include amounts related to our contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenue includes payments received in advance of performance under the contract. Our unbilled receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Unbilled receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue.

Allowance for Doubtful Accounts

We adjust accounts receivable down to net realizable value with its allowance methodology. In determining the allowance for doubtful accounts for estimated losses, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon historical collection experience, financial condition of the client and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. The allowance for doubtful accounts was nil at September 30, 2021. The Company believes that its reserve is adequate, however results may differ in future periods. For the nine months ended September 30, 2021 and 2020, bad debt expense totaled $0.

3343

Table of Contents

Research and Development

We account for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred.

Stock Based Compensation

All stock-based payments to employees and to nonemployee directors for their services as directors consisted of grants of restricted stock and stock options, which are measured at fair value on the grant date and recognized in the statements of operations as compensation expense over the relevant vesting period. Restricted stock payments and stock-based payments to nonemployees are recognized as an expense over the period of performance.

Such payments are measured at fair value at the earlier of the date a performance commitment is reached, or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable, the measurement date is the date the award is issued.

On October 29, 2014, our common stock commenced trading on OTCQB and on September 21, 2018 on the NASDAQ Capital Market under the symbol “BSGM.” Fair value of options are typically determined by the sales prices of our common stock for the 10 trading days immediately preceding the date of the award.

Use of Estimates

Acquisition of Intellectual Property

Intellectual property acquired are accounted for under the acquisition method of accounting. This method requires the recording of acquired assets, including separately identifiable intangible assets, and assumed liabilities at their acquisition date fair values. The method records any excess purchase price over the fair value of acquired net assets as goodwill.

The acquired intellectual property from the Trek acquisition was considered unproven compounds, the success of which was uncertain at the time of the acquisition. Accordingly, the fair value of the consideration paid was charged as acquired research and development to current period operations.

Income Taxes

Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carryforwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. We record an estimated valuation allowance on our deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized. We recognize a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

3444

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required under Regulation S-K for “smaller reporting companies.”

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required under Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we carried out an evaluation, with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Controls over Financial Reporting

There have been no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-(f) of the Exchange Act) that occurred during the last fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

3545

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Aurigene Pharmaceutical Services LTD vs. ViralClear Pharmaceuticals Inc. and BioSig Technologies, Inc.

On September 23, 2021, the Company ~~contends that it is not~~entered into a ~~proper party to the lawsuit since the agreements at issue were signed~~settlement agreement with Aurigene for a sum of $1,000,000 payable in three installments of $400,000, $300,000, and $300,000 on September 30, 2021, December 31, 2021 and March 31, 2022, respectively, with no admission or concession by a subsidiary. The Company also contends that Aurigene is not entitled to the relief it seeks, because it did not meet its own obligations under the contracts, including several manufacturing milestones. The Company intends to defend itself vigorously.either party.

From time to time, we may become involved in ~~other~~ various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in ~~these or other~~such matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

There are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our common stock is an adverse party or has a material interest adverse to our interest.

ITEM 1A. RISK FACTORS

~~Not required under Regulation S-K~~The following description of risk factors includes any material changes to risk factors associated with our business, financial condition and results of operations previously disclosed in Item 1A. “Risk Factors” of our annual report on Form 10-K for ~~“smaller reporting companies”~~ the fiscal year ended December 31, 2020, as filed with the SEC on March 15, 2021. Our business, financial condition and operating results can be affected by a number of factors, whether currently known or unknown, including but not limited to those described below, any one or more of which could, directly or indirectly, cause our actual financial condition and operating results to vary materially from past, or from anticipated future, financial condition and operating results. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results, and stock price.

The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding other statements in this Form 10-Q. The following information should be read in conjunction with the condensed consolidated financial statements and related notes in Part I, Item 1, “Financial Statements” and Part I, Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this Form 10-Q.

The COVID-19 pandemic and related U.S. supply chain issues, including shipping and raw material disruptions, could have a continuing material impact on the global supply chain, which could adversely impact our business results and financial condition.

We rely on a limited number of suppliers and manufacturers, particularly in the production and service of our PURE EP™ System. In the event of interruption within our supply chain due to global shortages of key supplies, materials or products, we may not be able to increase capacity from other sources or develop alternative or secondary sources without incurring substantial additional costs and/or delays.

Prolonged shortages in raw material supplies, delays and disruptions to manufacturing, production and shipping, congestion at key shipping ports and shortages in warehouse storage space due to the supply chain crisis, could significantly and adversely affect our business if one or more of our manufacturers or suppliers are impacted by any interruption at a particular location or in relation to a particular material or component. To the extent the disruptions in the U.S. supply chain continue, our business, particularly the manufacturing of the PURE EP™ System, could be adversely affected.

Table of Contents

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On ~~January 13,~~August 17, 2021, BioSig Technologies, Inc. issued ~~18,868~~150,000 shares of common stock to ~~IRTH Communications LLC~~Mayer & Associates in exchange for consulting services rendered with a fair value of ~~$75,283,~~$447,000, pursuant to a service renewal agreement, dated ~~December 11, 2019.~~July 29, 2021.

On ~~March 29,~~August 17, 2021, BioSig Technologies, Inc issued ~~125,000, 125,000 and 75,000~~37,500 shares of common stock (each) to ~~Draper, Inc., Carriage House Capital Corp.~~Barry Kaplan and ~~Church & Keeler, Inc., respectively,~~Andrew Kaplan, in exchange for consulting services with an aggregate fair value of ~~$1,384,500,~~$223,500, pursuant to consulting ~~agreements entered into in March~~agreement, dated August 11, 2021.

The issuance of the shares of common stock to ~~IRTH, Draper, Inc., Carriage House Capital Corp.~~Mayer & Associates, Barry Kaplan and ~~Church & Keeler, Inc.~~Andrew Kaplan were not registered under the Securities Act, or the securities laws of any state, and the shares of the common stock were issued in reliance on the exemption from registration under the Securities Act pursuant to Section 4(a)(2) of the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None

3647

Table of Contents

ITEM 6. EXHIBITS

1.1	Underwriting Agreement, dated July 2, 2021, by and between BioSig Technologies, Inc. and Laidlaw & Company (UK) Ltd. (incorporated by reference to Exhibit 1.1 to the Form 8-K filed on July 6, 2021)
3.1	Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form S-1 filed on July 22, 2013)
3.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.2 to the Form S-1 filed on July 22, 2013)
3.3	Certificate of Second Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.3 to the Form S-1 filed on July 22, 2013)
3.4	Certificate of Third Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.5 to the Form S-1/A filed on January 21, 2014)
3.5	Certificate of Fourth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.6 to the Form S-1/A filed on March 28, 2014)
3.6	Certificate of Fifth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on August 21, 2014)
3.7	Certificate of Sixth Amendment to the Amended and Restated Certificate of Incorporation of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 25, 2016)
3.8	Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on November 9, 2017)
3.9	Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on February 16, 2018)
3.10	Certificate of Seventh Amendment to the Amended and Restated Certificate of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 10, 2018)
3.11	Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.4 to the Form S-1 filed on July 22, 2013)
3.12	Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on September 27, 2019)
3.13	Amendment No. 1 to Amended and Restated Bylaws of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on October 22, 2019)
3.14	Certificate of Designations of Series F Junior Participating Preferred Stock of BioSig Technologies, Inc. (incorporated by reference to Exhibit 3.1 to the Form 8-K filed on July 17, 2020)
4.1	Form of Underwriter Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K filed on July 6, 2021)
31.01*	Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.02*	Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.01*	Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101 INS*	Inline XBRL Instance Document
101 SCH*	Inline XBRL Taxonomy Extension Schema Document
101 CAL*	Inline XBRL Taxonomy Calculation Linkbase Document
101 DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document
101 LAB*	Inline XBRL Taxonomy Labels Linkbase Document
101 PRE*	Inline XBRL Taxonomy Presentation Linkbase Document
104*	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.

3748

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIOSIG TECHNOLOGIES, INC.

Date: ~~May 17,~~November 15, 2021	By:	/s/ Kenneth L. Londoner
		Kenneth L. Londoner
		Chairman & Chief Executive Officer (Principal Executive Officer)


Date: ~~May 17,~~November 15, 2021	By:	/s/ Steven Chaussy
		Steven Chaussy
		Chief Financial Officer (Principal Accounting Officer)

3849

0001530766 us-gaap:~~SeriesEPreferredStockMember us-gaap:RetainedEarningsMember 2020-12-31~~EmployeeStockOptionMember bsgm:EquityIncentive2012PlanMember 2012-10-19 iso4217:USD xbrli:shares

						Weighted-Average
				Weighted-Average		Remaining		Aggregate
	Shares			Exercise Price		Contractual Term		Intrinsic Value
Outstanding at December 31, 2020		3,568,497		$	5.59		7.0	$	110,961
Grants		489,500			4.38		10.0	$	-
Exercised		(9,375	)	$	2.96				-
Forfeited/expired		(268,585	)	$	7.53				-
Outstanding at March 31, 2021		3,780,037		$	5.31		7.50	$	308,891
Exercisable at March 31, 2021		2,626,129		$	5.34		6.77	$	228,066

Net loss	$	(804,642	)
Average Non-controlling interest percentage of profit/losses		29.8	%
Net loss attributable to the non-controlling interest	$	(239,421	)

Balance, December 31, 2020	$	802,269
Allocation of equity to non-controlling interest due to equity-based compensation issued		19,540
Net loss attributable to non-controlling interest		(239,421	)
Balance, March 31, 2021	$	582,388

BIOSIG TECHNOLOGIES, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

THREE AND NINE MONTHS ENDED ~~MARCH 31,~~SEPTEMBER 30, 2021

(In Thousands, Except Par Value and Share Amounts)